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ABSTRACT 
The malaria parasite, Plasmodium falciparum, is responsible for more than 3000 
deaths in Africa per day. The complex lifecycle of the parasite in the human and 
mosquito hosts requires a tight control of gene regulation. This area of the 
parasite’s biology is not well understood but recent advances in the application of 
molecular techniques to P. falciparum and the publication of the parasite genome 
sequence have provided the means to gain insight into mechanisms of gene 
regulation in the parasite.  
 
PfMyb2 is annotated as a putative transcription factor. It contains two Myb-like 
DNA-binding domains which have been cloned and demonstrated to bind Myb 
regulatory elements in the promoters of two P. falciparum genes, therefore 
validating it as a DNA-binding protein (Meyersfeld, 2005). In this study the full 
length PfMyb2 gene was cloned into the pGEX-4T-2 expression vector and 
induced to express recombinant PfMyb2 protein fused to a glutathione-S-
transferase (GST) tag in E. coli. This prokaryotic expression system produced 
mainly insoluble recombinant protein. The protein was extracted from the 
bacterial inclusion bodies, solubilised, refolded and purified using affinity 
chromatography. A 500ml culture yielded ~20-40ug purified PfMyb2-GST in 
total.  
 
Bioinformatic analysis revealed homologues of PfMyb2 in other Plasmodium 
species and an unusually high homology to the human CDC5 protein, a 
multifunctional protein involved in transcriptional regulation of the cell cycle as 
well as in pre-mRNA splicing. PfMyb2 and CDC5 both contain a REB1 domain, 
part of a yeast protein. This domain binds to DNA to enhance transcription factor 
binding and it may also remodel chromatin resulting in activation or silencing of 
promoters. Based on the high homology to CDC5, including the REB1 domain, it 
is speculated that PfMyb2 is a multifunctional protein that plays a role in 
transcription, chromatin remodelling and RNA processing in the parasite.  
 
The full length recombinant PfMyb2 produced in this study lays the foundation 
for future studies to validate these speculative functions. 
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1.  INTRODUCTION 
1.1 The impact of malaria 
Malaria is a disease caused by four species of protozoan parasites belonging to the 
genus Plasmodium. It affects between 300-600 million people worldwide and is 
responsible for more than 1 million deaths annually (Snow et al., 2005, Greenwood et 
al., 2005). The Plasmodium parasites are transmitted to humans by the female 
Anopheles mosquito and the geographical distribution of this insect vector therefore 
determines which regions will be affected by malaria. The disease is endemic to 
Africa, Asia, Central and South America and hence is a problem mainly in developing 
countries (Snow et al., 2005). The disease not only causes ~3000 deaths per day 
(mostly children in sub-Saharan Africa) having great social implications, but it also 
affects productivity and negatively impacts on the economy of the endemic areas. In 
Africa alone, the total estimated cost of malaria is US$ 12 billion. Plasmodium 
falciparum (P. falciparum) is the major cause of malaria in Africa (Greenwood et al., 
2005). In South Africa this disease affects only certain areas of the Limpopo province, 
Mpumalanga and KwaZulu Natal (www.doh.gov.za/facts/stats-
notes/2004/malaria.htm). 
 
Efforts to eradicate malaria were implemented after the end of World War II through 
the use of insecticide to kill the mosquito vector and chloroquine to treat the disease. 
In many areas this was successful and these efforts have impacted greatly on the 
distribution of the disease worldwide. Certain areas however still remain affected and 
in the last decade there has been a resurgence of malaria, in Africa particularly. A 
number of factors have contributed to this. Civil unrest and war in malaria areas has 
lead to a lack of medical facilities and treatment for the disease. Global warming may 
play a role by increasing mosquito vector survival in previously cooler areas, resulting 
in the larger distribution of the vector and spread of malaria. However, the most 
relevant factor for the resurgence of malaria is the resistance that the parasite is 
developing to drugs commonly used to fight the disease, as well as resistance in 
mosquitoes to insecticides used to control the vector (Greenwood et al., 2005). With 
the increase in drug-resistant Plasmodium species, there is a greater urgency to find 
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new drug targets and interventions to control the disease. By studying the parasite’s 
biology and pathogenesis, novel means for intervention may be uncovered.  
 
1.2 The P. falciparum lifecycle 
Plasmodium  falciparum has evolved a complex lifecycle to survive within the human 
host and the insect vector. During its lifecycle this single celled parasite will invade 
human hepatic and erythrocytic cells, while avoiding the host immune response. Once 
taken up by the mosquito it will need to survive in the gut and salivary glands of the 
vector. Throughout this complex lifecycle the parasite undergoes many morphological 
changes as seen in figure 1.2.1.  
 
 
Figure 1.2.1: The lifecycle of P. falciparum  
This diagram of the P. falciparum lifecycle is adapted from the Center for Disease Control and 
Prevention web page (http://www.dpd.cdc.gov/dpdx/Default.htm).  
Explanation of the lifecycle stages is in the text. 
 
The process of human invasion begins when a P. falciparum-infected mosquito takes 
a blood meal, injecting sporozoite forms of the parasite beneath the skin or into the 
bloodstream. The sporozoites move on to invade hepatic cells of the liver, where they 
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undergo a number of asexual division cycles, over a period of two weeks, to form 
thousands of merozoites (stages 1-4 of A in figure 1.2.1). 
 
The merozoite forms of the parasite enter into the bloodstream where each one is able 
to invade an erythrocyte. Once in the erythrocyte the parasite will undergo different 
morphological changes over a 48 hour period to produce more merozoites. These 
stages are known as rings, trophozoites, schizonts and merozoites (stages 5-6 of B in 
figure 1.2.1). This intraerythrocytic cycle of the parasite is responsible for the 
pathogenesis of malaria. Each merozoite that infects an erythrocyte is able to produce 
up to 20 new merozoites, which burst from the infected cell. This process destroys the 
infected cells, increases parasite number rapidly due to successive infections of 
erythrocytes and results in the onset of disease symptoms. Destruction of the red 
blood cells leads to chills, fevers and anaemia. Small blood vessels become blocked 
with parasitised erythrocytes adhering to their lining, causing a decreased blood and 
oxygen supply to tissues. The inflammatory response of the host is also affected. All 
these factors contribute to cause severe malaria (Miller et al., 2002). 
 
It is also during the intraerythrocytic stage that sexual differentiation of P. falciparum 
takes place. This is important for dissemination of the disease as the Anopheles 
mosquito takes up gametocytes during a blood meal. Upon infection of the 
erythrocyte some parasites are induced to produce either macro- or microgametocytes 
(stage 7 of B in figure 1.2.1) instead of undergoing asexual division. Once ingested by 
the mosquito the gametocytes undergo gametogenesis. During this phase a single 
female and male gametocyte produce one female gamete and 8 male gametes 
respectively. The gametes fuse to form a zygote that undergoes meiotic divisions 
within the oocyst and produce haploid sporozoites. These then move from the 
mosquito gut into the salivary glands, where they will eventually be injected into 
another human host during a blood meal (stages 8-12 of C in figure 1.2.1) (Lobo and 
Kumar, 1998). 
 
This complex lifecycle that P. falciparum has developed has been well studied. The 
biology of the parasite such as mechanisms of erythrocyte invasion, metabolism, host 
immune evasion, cell cycle control and differentiation, as well as induction of asexual 
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division and sexual differentiation are slowly being elucidated. The application of 
molecular techniques to P. falciparum and the sequencing of the parasite genome 
have resulted in major advances in our knowledge. However, not much is known 
about how the parasite regulates the different stages of its lifecycle but it is clear that a 
tight control of gene expression is required (Deitsch, 2004). Therefore the study of 
gene regulation is of great importance and may lead to novel means of intervention 
and control of this important human pathogen. 
 
1.3 Eukaryotic gene regulation 
In eukaryotes the initiation of transcription is the most important step in gene 
expression. The RNA polymerase II (pol II) enzyme complex is responsible for the 
transcription of protein coding genes into pre-mRNA. General transcription factors 
such as TFIIA, TFIIB, TFIIC and TFIID, including the TATA binding protein (TBP), 
guide pol II to the transcription-initiation site (figure 1.3.1) to begin transcription of 
the gene. Promoters in eukaryotes have a bipartite structure containing a basal 
promoter that is regulated by an upstream enhancer element. Promoters are generally 
close to transcription start sites, whereas enhancer sequences can be located 50kb or 
more from the coding region. Specific transcription factors bind to promoters and 
only activate certain genes, while the general transcription factors are required by pol 
II to transcribe all activated genes. Initiation of transcription is influenced by several 
parameters including chromatin structure and concentration of specific transcription 
factors. Post-transcriptional mechanisms such as mRNA stability and processing 
provide further control of gene expression (Lodish et al., 2000). 
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Figure 1.3.1: Transcriptional activation of genes 
This figure was adapted from Lodish et al. (2000) and depicts transactivation of genes in eukaryotes by 
general transcription factors and the initiation of transcription by RNA polymerase II. 
(Transcription factors: TFIID, TFIIE, TIIF and TFIIH; TATA binding protein: TBP; 
C-terminal repeat domain: CTD; Adenosine triphosphate: ATP; Adenosine diphosphate: ADP; 
Ribonucleoside triphosphates: NTPs; RNA polymerase II: pol II)  
 
1.4 The P. falciparum genome study and parasite biology   
1.4.1 P. falciparum genome 
The full genome sequence of P. falciparum (Gardner et al., 2002) has revealed an 
extreme AT bias, which distinguishes it from other genomes. Over 80% of its genome 
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is made up of A-T nucleotides and intergenic regions can contain up to 90%. Genes 
are monoscistronically transcribed and the resulting mRNA contains 3’ and 5’ 
untranslated regions, a poly-A-tail and a 5’cap. Genes are under the control of 
bipartite promoters, which consist of a basal promoter and an upstream enhancer 
element. Some of these promoters contain homopolymeric (dA:dT) tracts. Unlike 
eukaryotes, these cis-acting elements are located much further upstream from the 
transcriptional start site (Horrocks et al., 1998, Deitsch, 2004). The promoters 
discovered in P. falciparum are discussed in more detail in section 1.5.3.1.  
1.4.2 P. falciparum proteome 
The P. falciparum genome encodes ~5300 proteins and 60% of these are hypothetical 
with no known function. Parasite proteins that have homology to those in eukaryotes 
are often very large and can be up to 50% bigger than their eukaryote homologues.  
Many contain low complexity regions made up of stretches of repeating amino acids, 
usually asparagines (Aravind et al., 2003, Gardner et al., 2002). The function of these 
regions is not certain but they may be involved in protein-protein interactions as they 
loop out around the protein. These regions are thought to change frequently and may 
therefore play a role in host immune evasion as antibodies will no longer recognise 
the exposed and changed epitope (Brocchieri, 2001).  
1.4.3 P. falciparum transcriptome 
Microarray analysis of the intraerythrocytic lifecycle showed that genes with related 
functions are expressed at specific stages, even if they are not clustered in the genome 
and each lifecycle stage expresses different levels of mRNA. Many of the proteins 
encoded by these genes are stage-specific and expressed to perform certain functions 
at the particular lifecycle stage. Even the common ‘house keeping’ genes have 
varying levels of expression at various stages. All these factors demonstrate that gene 
expression is tightly controlled in the parasite (Bozdech et al., 2003, Le Roch et al., 
2003). 
1.4.4 The study of P. falciparum gene regulation 
The study of gene regulation in P. falciparum has been limited in the past, but 
molecular techniques have recently been developed in P. falciparum (De Koning-
Ward et al., 2000) and the release of the full P. falciparum genome sequence has 
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facilitated genome mining approaches to study gene regulation in the parasite 
(Gardner et al., 2002). The process of gene expression in P. falciparum occurs via the 
interaction of cis-regulatory sequences and trans-acting factors that drive gene 
transcription. Factors controlling gene regulation of the parasite lifecycle, as well as 
mechanisms to determine which copies of the multi-gene families are expressed 
during the different stages are slowly being elucidated (Deitsch, 2004). 
 
Molecular techniques such as transfections, reporter gene analysis, deletion analysis 
of regions upstream of genes and electromobility shift assays (EMSA) have all been 
crucial in the discovery of DNA regulatory sequences and transcription factors. 
Bioinformatic genome mining has also revealed putative cis- and trans-acting factors 
involved in gene regulation that have been found in other organisms. As these 
elements are discovered, they need to be validated in P. falciparum using molecular 
techniques. Genome mining, however, is based on sequence homology and P. 
falciparum genes and proteins are quite divergent from higher eukaryotes, therefore it 
may not be as effective in the search for homologous proteins found in other 
eukaryotes (Deitsch, 2004). The use of proteomics (Florens et al., 2002), serial 
expression of gene analysis and microarrays (Bozdech et al., 2003, Llinas et al., 2006, 
Florent et al., 2004) has led to the study of the regulation of multiple gene families or 
groups of genes simultaneously. 
 
1.5 Aspects of gene regulation in P. falciparum 
The general transcription-associated proteins have been identified in P. falciparum, 
including RNA polymerase I, II and III, TFIIB, TFIIE and the TATA binding protein 
of TFIID (Callebaut et al., 2005, Coulson et al., 2004). Proteins involved in post-
transcriptional gene regulation and chromatin remodelling have also been identified 
(Horrocks et al., 1998, Kumar et al., 2004). Therefore it is thought that a multi-level 
control of gene expression may take place in the parasite, using different control 
mechanisms.  
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1.5.1 Epigenetic gene regulation 
The structure of the chromatin surrounding the genes of P. falciparum is likely to 
have an effect on transcriptional control of the genes. Protein complexes allow the 
DNA to dissociate from the histones in an ATP-dependent reaction. This renders the 
DNA promoter sites more accessible to transcription factors and therefore activates 
these promoters (Lodish et al., 2000). The genes encoding components of the enzyme 
complexes ISWI and SNF2L (involved in nucleosome remodelling), histone acetylase 
and deacetylase (involved in histone modification) have all been identified in the P. 
falciparum genome. It is thought that each lifecycle stage of the parasite may contain 
varying arrangements of chromatin organisation and that this may control which 
genes are expressed at the different developmental stages (Coulson et al., 2004).  
 
The promoter structure of P. falciparum may also alter the form of the chromatin 
flanking the gene sequences. The homopolymeric dA:dT tracts found in some parasite 
promoters form a rigid structure in the DNA and may render the promoter site more 
accessible to transcription factors or increase its affinity for transcription factor 
binding. Homopolymeric tracts are usually unstable and lost during DNA replication, 
however there has been a strong selective advantage for these tracts in P. falciparum 
as they are found throughout the genome, generally flanking genes (Horrocks et al., 
1998), implying that they are involved in gene regulation. 
 
The var genes are a family of multi-copy genes that encode antigenic surface proteins 
(one P. falciparum parasite may contain between 50 to 150 var genes). Only one gene 
is expressed in a single parasite at a time, implying that the parasite is able to switch 
expression of the var genes, which helps to evade the host’s immune response. Var 
genes are located at the subtelomeric regions of the chromosomes and epigenetic 
control of their expression has been demonstrated (Scherf et al., 1998). The silent 
information regulator 2 protein (PfSir2) binds to the subtelomeric region of the 
parasite’s chromosome, altering chromatin structure through histone hypoaceteylation 
and the induction of a heterochromatin gradient in this region. This renders the var 
genes silent and the removal of PfSir2 results in their expression (Freitas-Junior et al., 
2005).  
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1.5.2 Post-transcriptional control of gene regulation 
Once RNA is produced it undergoes a number of processes before it is translated into 
protein. Post-transcriptional control mechanisms alter gene expression by 
manipulating various steps of the mRNA processing cycle and therefore alter the 
amount of protein produced (Lodish et al., 2000). Coulson et al. (2004) discovered 
through sequence alignments that the most abundant protein involved in post-
transcriptional modification of pre-mRNA present in the P. falciparum genome is the 
CCCH-type zinc finger. The genome appears to contain twice the number of CCCH-
type zinc fingers than higher eukaryotes. This motif functions at a post-transcriptional 
level by playing a role in mRNA stability, localisation and translation. Homologues of 
the CCR4-NOT coactivator were also discovered during this study. This complex has 
deadenylase activity, which affects the rate of mRNA translation and decay. This 
suggests that gene regulation in P. falciparum also relies on post-transcriptional 
controls through mRNA stability. Gunasekera et al. (2007) discovered three putative 
regulatory repeats upstream of gene clusters expressed in chloroquine-treated P. 
falciparum cultures. These motifs were able to drive reporter gene expression, 
however, gel mobility shift assays revealed that none of the motifs were bound by 
proteins at the DNA level but two were bound at the RNA level indicating post-
transcriptional control of gene expression through mRNA interactions.  
 
Post-transcriptional control of genes may be a more efficient way of controlling 
protein levels in P. falciparum. The parasite encounters rapid, but predictable changes 
in environment during its lifecycle. Therefore P. falciparum gene regulation can occur 
in an ordered, predictable manner using post-transcriptional control which allows a 
quick response to the new environment (Coulson et al., 2004). The gametocytes in the 
human host contain some mRNA which are not translated in the erythrocytic stage, 
but are rapidly activated by post-transcriptional mechanisms in the mosquito vector to 
produce proteins required for further development (Florens et al., 2002). 
1.5.3 Transcriptional gene regulation 
The gene structure in the parasite is similar to that of eukaryotes, however, some of 
the regulatory sequences found in the enhancer regions of the promoters share no 
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homology with those found in other eukaryotes. These promoters do not drive 
reporter gene expression in cultured mammalian COS-7 cells and conversely, viral 
promoters (such as the SV40) that are functional in eukaryotes do not drive reporter 
gene expression in P. falciparum (Horrocks et al., 1998). Therefore it is likely that the 
transcription factors that bind these enhancer sequences are specific to Plasmodium 
species and share no or very little homology with other eukaryotic transcription 
factors. 
1.5.3.1 Regulatory sequences in P. falciparum 
Promoter regions with homology to those found in eukaryotes have been identified in 
P. falciparum. TATA motifs have been demonstrated in the promoters of several P. 
falciparum genes and P. falciparum TBP has also been identified (Ruvalcaba-Salazar 
et al., 2005, McAndrew et al., 1993). Gene promoters containing the TATA box motif 
include proliferating cell nuclear antigen (PfPCNA) (Horrocks and Kilbey, 1996), 
heat shock proteins (hsp) (Su and Wellems, 1994), calmodulin (Robson and Jennings, 
1991) and two sexual stage specific genes: pfs16 and pfs25 (Dechering et al., 1999).  
 
Other common regulatory sequences in eukaryotes are the CpG islands. These contain 
a 20-50 nucleotide stretch ~100bp from the transcriptional start site of genes and are 
recognized by the transacting protein, SP1, which drives transcription (Lodish et al., 
2000). The P. falciparum homologue of this transcription factor has not been 
identified, however, CG-rich regions have been demonstrated in the parasite 
transcriptional start sites for the hsp86 (Wu et al., 1995) and PfPCNA genes 
(Horrocks and Kilbey, 1996) and may have a role to play in transcriptional activation.  
 
OCT1 has also been identified in promoters of Plasmodium species and the two 
regulatory regions, ATTCAAAT and ATGCATAT, are located 270bp and 230bp, 
respectively, upstream of the transcriptional start site of the PfPCNA gene (Horrocks 
and Kilbey, 1996). Putative CAAT box motifs have been found in the promoters of P. 
falciparum sexual stage-specific pfs25 and pgf27 genes (Dechering et al., 1999, 
Olivieri et al., 2008). Their functional relevance, although well known as regulatory 
motifs to which transcription factors bind to in higher eukaryotes, still needs to be 
elucidated in P. falciparum.  
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A number of regulatory sequences that have no homology to higher eukaryotic 
promoters have also been identified in the P. falciparum genome. These were 
discovered through deletion analysis of upstream regions flanking the initiation start 
sites, EMSA studies and reporter gene expression.  Horrocks and Lanzer (1999) were 
the first to discover a regulatory sequence essential for promoter activity for the 
glycophorin binding protein 130 (GBP130) gene. This was a 5bp sequence that was 
located in a region between 544-507bp from the transcriptional start site. It bound 
nuclear factors and was essential in GBP130 expression.  
 
Bioinformatics has also been utilised to discover P. falciparum specific cis-regulatory 
sequences that may be essential in gene expression. This approach identifies 
sequences that are over-represented and upstream of clustered or co-ordinately 
expressed genes. Militello et al. (2004) used this approach for heat shock protein (hsp) 
genes in P. falciparum and identified a G-box element which contained two copies of 
the sequence, (A/G)NGGGG(C/A), in palindromic form. These sequences were 
validated using transfection studies and reporter gene expression. The G-box was 
located 195bp from the transcriptional start site and other genes were also found to 
contain single G-boxes, suggesting that the palindromic form is not essential for gene 
expression. However, how this regulatory sequence controls transcription has still not 
been elucidated. A number of other regulatory elements have been demonstrated in a 
few P. falciparum promoters (Wickham et al., 2003, Osta et al., 2002, Lopez-Estrano 
et al., 2007, Tham et al., 2007). The most recent study was performed by Young et al. 
(2008) using an in silico method that takes into account the extreme AT-rich regions 
of the parasite genome. They discovered ~30 putative regulatory sequences upstream 
of a number of genes and gene families that function in various aspects of the P. 
falciparum lifecycle. These regions still need to be validated using molecular 
techniques. This study, however, emphasises the importance of bioinformatics in the 
discovery of factors pertaining to P. falciparum gene regulation.  
1.5.3.2 Transcriptional control of P. falciparum gene expression 
It is thought that P. falciparum has developed a unique set of transcription factors, 
which would not be identified in the genome through simple homologous sequence 
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alignments to other eukaryotic transcription factors. During sequence homology 
searches, Coulson et al. (2004) found that the P. falciparum genome encodes only one 
third of the proteins involved with transcriptional regulation when compared to other 
eukaryotic genomes. This could support the fact that unique transcription factors have 
evolved in the parasite. Another school of thought to explain the small number of 
identified transcription factors in P. falciparum is that transcriptional activation 
occurs using fewer trans-acting elements. A study on the identification of regulatory 
sequences by Van Noort and Huynen (2006) indicated that P. falciparum genes have 
four to five regulatory sequence sites per gene. They speculate that different 
combinations of transcription factors bind to these sequences and this combinatorial 
effect drives gene expression. They also speculate that transcription factors may 
contain overlapping binding sites for regulatory sequences. Therefore fewer trans-
acting elements are needed as they can bind to promoters in different combinations to 
produce differential gene expression and this explains the relative lack of transcription 
factors in the P. falciparum genome.  
 
Various studies using microarrays have demonstrated that gene expression appears 
well regulated during the various stages of the intraerythrocytic lifecycle, as only 
genes relating to particular functions for each stage are expressed when required (Le 
Roch et al., 2003, Bozdech et al., 2003, Llinas et al., 2006). This expression pattern 
also seems to be consistent in three different strains of P. falciparum (3D7, Dd2 and 
HB3) (Llinas et al., 2006). Unless the parasite differentiates into its sexual forms, it 
undergoes a repeating cycle of gene expression to complete the intraerythrocytic 
cycle. Therefore the parasite will most likely contain a rigid program of gene 
regulation and a single induction event may lead to gene expression in a cascade-like 
manner. This less sophisticated process of gene regulation would require fewer 
transcription factors to initiate RNA synthesis (Bozdech et al., 2003).  
1.5.3.3 Specific transcription factors in P. falciparum 
Specific transcription factors in P. falciparum are slowly being discovered using 
molecular and bioinformatic techniques, however, until these proteins are 
characterised they remain only putative transcription factors. Hybridisation studies 
performed by Kumar et al. (2004) revealed a number of putative transcription factors 
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in the nuclear extracts of P. falciparum parasite cultures (containing either asexual, 
sexual or stressed parasites) that bound to eukaryotic cis-regulatory elements. 
However, none of these were differentially expressed in the different parasite cultures. 
Eight of these putative transcription factors (c-Myb, CREB, EGR, MEF-1, NFkB, 
E2F1, Smad3/4 and HSE) were further analysed using EMSA. Only two, c-Myb and 
MEF-1, had high specific binding for their regulatory elements. It is thought that the 
others may have a broader range of DNA binding specificity. Gissot et al. (2004) have 
also discovered five putative P. falciparum-specific transcription factors that are 
developmentally regulated during the intraerythrocytic cycle. These are Pfhmg2, 
pfphD2, pfmyb3 (PF10_0143), pfphDB (PFL1905w) and pfkrox (MAL13P1.76). 
Table 1.5.1 summarises information available on P. falciparum transcription factors 
from the literature as well as online databases, PlasmoDB (www.plasmodb.org) and 
DBD: Transcription factor prediction database (www.transcriptionfactor.org). Many 
of these proteins are only hypothetical, emphasising the unusual composition of the P. 
falciparum genome and the possibility of the parasite evolving its own unique set of 
transcription factors.  
 
These studies on gene regulation in P. falciparum have shown that gene expression in 
the parasite lifecycle is driven by transcription initiation. These transcription factors, 
albeit specific or general, may in turn be controlled by other epigenetic or post-
transcriptional factors regulation.  
 
1.6 The Myb-gene family and proteins 
The first Myb gene identified was the oncogene, v-Myb, from the avian myeloblastosis 
virus.  This gene was formed through recombination when the retrovirus was inserted 
into chicken cellular Myb (c-Myb) DNA. This led to the discovery of the Myb genes in 
vertebrates and other eukaryotes. This gene family and the proteins they encode are 
evolutionarily conserved amongst eukaryotes and have been found in fungi, plants 
and animals. Myb proteins bind to DNA and play a role in transcription of genes 
involved in cell proliferation and differentiation. Three members of the vertebrate 
Myb gene exist: A-myb, B-myb and c-myb (Oh and Reddy, 1999, Lipsick, 1996). In 
vertebrates, the c-Myb gene and protein have been the most extensively studied of the 
Myb gene family. 
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Table 1.5.1: Putative transcription factors in P. falciparum. 
This information was summarised from online resources (PlasmoDB:wwwplasmodb.org and 
DBD:www.transcriptionfactor.org) and the literature (Kumar et al., 2004, Gissot et al., 2004, Boschet 
et al., 2004, Meyersfeld, 2005). 
 
Transcription factor Possible protein function  Reference 
CREB  cAMP response element Kumar et al., 2004 
E2F1  Cyclin E regulation Kumar et al., 2004 
EGR  Early grown response element Kumar et al., 2004 
HSE Heat shock element Kumar et al., 2004 
Smad3/4  Involved in signaling Kumar et al., 2004 
MEF-1  Myogenic cell differentiation Kumar et al., 2004 
NFkB  Type 1 interferon system regulator Kumar et al., 2004 
PF13_0088 (PfMyb1) Cell cycle and differentiation Boschet et al., 2004; 
PlasmoDB 
PFL0465c/ MAL13P1.76 Zinc finger transcription factor 
(pfkrox) 
Gissot et al., 2004; DBD 
MAL13P1.302 Putative SUMO ligase DBD 
MAL8P1.131 Putative Gas41 homologue PlasmoDB 
PF08_0056 Putative zinc finger protein DBD 
PF10_0058 Putative DnaJ protein DBD 
PF10_0143 (PfMyb3) Putative transcriptional activator 
ADA2; Myb family proteins  
Gissot et al., 2004; PlasmoDB 
PF11_0192 Putative histone acetyltransferase DBD 
PF11_0293 Putative multiprotein bridging factor 
type 1 
DBD 
PF13_0043 Putative CCAAT-binding transcription 
factor 
PlasmoDB 
PFA0470c Putative cold-shock protein DBD 
PFE0355c Putative serine protease; subtilisin 
family 
DBD 
MAL13P1.213 Putative transcription activator PlasmoDB 
PF10_0293 Putative transcription factor PlasmoDB 
PF10_0327 (PfMyb2) Putative transcription factor Meyersfeld, 2005; PlasmoDB 
PF13_0054 Putative transcription factor PlasmoDB 
PFB0290c Putative transcription factor PlasmoDB 
PFD0360w Putative transcription factor PlasmoDB 
PFE1025c Conserved hypothetical protein DBD 
PFE1515w Conserved hypothetical protein PlasmoDB 
PFF0490w Conserved hypothetical protein PlasmoDB 
PFI1425w Conserved hypothetical protein PlasmoDB 
PF11_0049 Conserved hypothetical protein DBD 
PFA0210c Conserved hypothetical protein PlasmoDB 
PFC1060c Conserved hypothetical protein DBD 
PFL1905w (pfphDB) Conserved hypothetical protein Gissot et al., 2004 
PF10_0091 Hypothetical protein DBD 
PF11_0469 Hypothetical protein DBD 
PF14_0058 Hypothetical protein DBD 
PF14_0170 Hypothetical protein DBD 
PF14_0608 Hypothetical protein DBD 
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Figure 1.6.1 The general structure of Myb proteins. 
Myb family proteins contain three amino terminal DNA-binding domains designated R1, R2 and R3 
(red). A transactivation domain (yellow) is located downstream from the DNA-binding domains and 
the carboxyl terminus contains a negative repressor element (grey). 
 
The general structure of the Myb proteins is illustrated in figure 1.6.1. The DNA-
binding domain defines the Myb family proteins. These amino terminal domains 
consist of two to three tandem repeats designated R1, R2 and R3 respectively, 
however, some Myb proteins contain more repeats. Two of the three motifs, usually 
R2 and R3, form two helix-turn-helix (HTH) repeats which bind a specific DNA 
regulatory sequence (PyAAG/TG), while the other motif stabilises the DNA-protein 
complex (Howe et al., 1990, Oh and Reddy, 1999). Each repeat motif contains 
regularly spaced tryptophan residues every 18 or 19 amino acids, as well as one 
highly conserved cysteine residue. The conserved tryptophan residues are thought to 
form a hydrophobic scaffold to stabilise the HTH repeat (Zargarian et al., 1999). Myb 
proteins contain a transactivation domain further downstream from the DNA-binding 
domain, consisting of acidic amino acid residues, while the carboxyl terminus 
functions as a negative repressor as truncated forms of the protein cause 
transactivation of transcription. Phosphorylation of certain amino acid residues in the 
protein and the interaction of Myb proteins with other co-activators and transcription 
factors result in enhanced promoter activity. Other proteins may contain Myb-like 
DNA-binding domains, however, not all these proteins act in transcriptional 
regulation (Oh and Reddy, 1999). An example is the TTAGGG repeat binding factor 
1, which contains a carboxyl Myb-like domain that facilitates DNA-binding at the 
telomeres (Konig et al., 1998). 
 
1.7 A specific P. falciparum transcription factor, PfMyb1 
PfMyb1 was the first specific transcription factor, not forming part of the general 
transcription machinery, described in P. falciparum (Boschet et al., 2004). It contains 
three imperfect Myb-like DNA-binding domains but unlike other eukaryotic Myb 
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proteins these motifs are located in the carboxyl terminus. It is able to bind Myb 
regulatory elements (MRE) such as the chicken mim-1 gene promoter and two 
putative MREs present in the promoters of two P. falciparum genes: pfmap1 and 
pfcrk1. This transcription factor binds DNA in a sequence specific manner and 
regulates genes involved in cell cycle and differentiation (Boschet et al., 2004, Gissot 
et al., 2005). Microarray studies by Gissot et al. (2005) showed that the highest 
expression levels of PfMyb1 were detected in the trophozoite stage. Knockdown of 
the PfMyb1 mRNA caused up-regulation of PfPk5, a gene involved in trophozoite to 
schizont transition, and therefore a reduction in growth of the parasite. Seven genes 
were down-regulated and these included PCNA1 which plays a role in DNA repair 
and cell cycle control; phosphoglycerate kinase involved in the glucose pathway; and 
two histone genes: H3 and H2A, that are controlled by a bi-directional promoter. 
Computational analysis revealed that only one of these genes did not contain a MRE 
in its promoter and chromatin immuno-precipitation assays followed by PCR 
amplification of gene promoters demonstrated that PfMyb1 was able to bind the 
promoters of six of these genes (including the promoter that did not contain a MRE). 
Therefore PfMyb1 directly regulated expression of these genes. Two genes (PfPk2 
and PfTbp) did not have direct interaction at the promoter level to PfMyb1 and 
therefore may have differential expression due to secondary effects as a result of the 
protein’s knockdown. These studies on PfMyb1 confirmed sequence homology data 
and indicated that it belongs to the well conserved family of Myb proteins found in 
other eukaryotes and plays a role in transcriptional regulation of genes (Boschet et al., 
2004, Gissot et al., 2005).  
 
1.8 A putative transcription factor, PfMyb2 
PfMyb2 was identified as a putative transcription factor in the Plasmodium database 
(PlasmoDB). It contains two Myb-like DNA-binding domains and is therefore a 
homologue of PfMyb1. Meyersfeld (2005) cloned the DNA-binding domains of this 
protein and analysed their function by EMSA studies. The domains were able to bind 
to the same MREs that PfMyb1 bound to, therefore verifying it as a DNA-binding 
protein and a possible transcription factor.  
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The current study was initiated to further characterise the full length PfMyb2 protein. 
This full length protein could be used further to prove its functionality as a P. 
falciparum transcription factor and may also reveal other roles the protein may play in 
the parasite’s biology. Therefore, this would lead to a better understanding of P. 
falciparum gene regulation and possibly other areas of the parasite’s biology. 
 
1.9 Objectives of the study 
 
The aim of this study was to: 
Clone the full-length PfMyb2 gene into expression vectors  
Express and purify the recombinant PfMyb2 protein 
Perform bioinformatic analysis on the PfMyb2 gene and protein. 
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2. MATERIALS AND METHODS 
2.1 P. falciparum parasite culture 
The P. falciparum 3D7 strain was cultured by adapting the culturing methods 
used in Ljungstrom et al. (2004). All culturing techniques were carried out under a 
sterile Bioflow laminar hood using aseptic techniques. The ASE Coolspin 34123-
606 centrifuge was used for all centrifugations during parasite culture.  
2.1.1 Preparation for parasite culture 
2.1.1.1 Culture media 
Incomplete medium was made up with 10.4g RPMI, 5.9g Hepes buffer, 4.0g 
glucose and 44mg hypoxanthine in one litre of autoclaved milliQ water. 
Gentamicin powder was added to a final concentration of 50ug/ml. The medium 
was stirred for one hour and then sterile filtered using an autoclaved filter unit and 
peristaltic pump. Incomplete medium was stored at 4°C. Complete medium 
consisting of 87.5ml incomplete medium, 10ml AB plasma and 2.5ml sterile 
filtered 5% sodium bicarbonate (NaHCO3) was prepared, stored at 4°C and kept 
for no longer than 5 days. 
2.1.1.2 Heat inactivation of plasma 
AB plasma was obtained from the South African National Blood Transfusion 
Service and heat inactivated by placing the bag at 56°C in a preheated water bath 
for 2 hours. The plasma was then transferred, using aseptic techniques in a sterile 
hood, to 50ml Nunc tubes and centrifuged at 2500 revolutions per minute (rpm) 
for ten minutes at room temperature. The supernatant was transferred to 15ml 
Nunc tubes and stored at -70°C in 10ml aliquots. 
2.1.1.3 Erythrocytes 
Blood was collected from healthy volunteers in acid citrate/dextrose (ACD) tubes 
and centrifuged using the ASE Coolspin 34123-606 centrifuge at 2500 rpm for 10 
minutes at 4°C to separate the blood into its three components –plasma, buffy coat 
and erythrocytes. The plasma and buffy coat were aspirated using a Pasteur 
pipette and peristaltic pump. The erythrocytes were washed in two volumes of 
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sterile filtered phosphate buffered saline (PBS, see below) and any remaining 
white blood cells were removed as before. The wash cycle was repeated three 
times and the erythrocytes were finally resuspended in one volume of incomplete 
medium and stored at 4°C for no longer than two weeks. 
 
PBS pH 7.2 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4.2H2O 
1.5mM KH2PO4  
2.1.2 Preparation of culture from frozen stocks 
Frozen stock cultures of P. falciparum 3D7 in 1.5ml cryo-tubes were thawed at 
37°C in a preheated water bath. The thawed culture was then moved to a 15ml 
Nunc tube and 100ul of sterile filtered 12% NaCl for each millilitre of culture was 
added in a drop wise fashion while swirling gently and then left at room 
temperature for five minutes. Nine volumes of sterile filtered 1.6% NaCl were 
added, mixed in gently and then centrifuged at 1500rpm for five minutes at room 
temperature. The supernatant was aspirated and the pellet was resuspended in nine 
volumes of a sterile filtered 0.9% NaCl/0.2% glucose solution and centrifuged as 
before. The supernatant was aspirated and the pellet resuspended in 750ul freshly 
washed 1:1 erythrocyte suspension. This was transferred to a small Nunc tissue 
culture flask (35cm2) and made up to 5ml with complete medium containing 20% 
AB plasma. The cultures were gassed for 20 seconds with a gas composition of 
5% CO2, 2% O2 and 93% N2 and the flask sealed tightly. The culture was 
incubated for 48 hours at 37°C. 
2.1.3 Culture maintenance 
2.1.3.1 Viewing parasite cultures 
Parasite cultures were viewed daily by preparing a smear of the culture on a glass 
microscope slide which was stained using the Rapindiff set staining kit based on 
the Giemsa Stain. The slide was viewed using the Carl Zeiss Axiostar microscope 
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under 1000x magnification and oil immersion. The percentage of parasitaemia 
was calculated using the following formula: 
 
 
 
 
 
Infected erythrocytes and total erythrocytes were counted in 5 fields containing 
more than 100 erythrocytes per field. An average percentage was calculated using 
the percentages from five fields. Cultures were maintained at a 5% parasitaemia 
and if the parasitaemia increased above 10% the culture would be moved to a 
larger flask or divided into two flasks.  
2.1.3.2 Changing medium of cultures  
Culture medium was changed once a day by gently tilting the flask and aspirating 
the medium. Fresh complete medium, warmed to 37°C was then added to a final 
volume of 5ml, 15ml or 30ml for a small (35cm2), medium (80cm2) and large 
flask (175cm2) respectively. Culture flasks were gassed for 20 seconds, sealed 
tightly and incubated at 37°C. As some of the erythrocytes are removed during the 
change of medium, washed erythrocytes were added when needed to maintain the 
culture at a 5% haematocrit.    
2.1.3.3 Parasite culture synchronisation  
Cultures were synchronised by sorbitol treatment (Lambros and Vanderberg, 
1979), which lyses erythrocytes that are infected with parasites in all stages except 
for those in the early ring stages. Cultures in large flasks containing parasites in 
mainly the early ring stage of development and parasitaemia greater than 10% 
were transferred to a 50ml Nunc tube, centrifuged at 1500rpm for 5 minutes at 
room temperature. The supernatant was aspirated, ten volumes of 5% D-Sorbitol 
added to the erythrocyte pellet, incubated at room temperature for 30 minutes and 
centrifuged as before. The supernatant was aspirated, the pellet resuspended in 
complete medium and made up to 30ml. Washed erythrocytes were added to 
%Parasitaemia =  
# Infected erythrocytes 
# Infected erythrocytes + # Uninfected erythrocytes 
X 100  
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maintain the 5% haematocrit. Cultures were gassed, sealed tightly and incubated 
at 37°C. 
 
2.2 DNA extraction and analysis 
2.2.1 DNA extraction protocol 
DNA extraction techniques were adapted from Ljungstrom et al. (2004). This 
protocol uses proteinase-K and phenol/chloroform to purify the DNA from 
cellular proteins and ethanol to precipitate the DNA.  
 
Parasite cultures with greater than 10% parasitaemia were transferred to a 30ml 
Beckman centrifuge tube, centrifuged in the Beckman J2-21 centrifuge using a 
JA-17 rotor at 1500rpm for 10 minutes at 4°C. The erythrocytes were resuspended 
in a total volume of 5ml PBS, lysed by adding 10ul of 5% saponin in PBS to each 
millilitre of suspension and left to stand for 5 minutes. The solution was 
centrifuged again at 3000rpm for 10 minutes at 4°C and the supernatant removed. 
The parasite pellet was washed with 10ml PBS and centrifuged as before and the 
wash cycle was repeated three times. After the third wash the pellet was 
resuspended in 300ul lysis buffer (see below) and 700ul water, incubated at 37°C 
for three hours while mixing by hand every 30 minutes. 400ul of a 1:1 ratio of 
phenol/chloroform was added. The contents were transferred to a 2ml Eppendorf 
tube, centrifuged using the desktop Eppendorf 5415R centrifuge at 13000rpm for 
5 minutes at 4°C. The aqueous phase was collected and 100ul of Tris-EDTA (TE) 
buffer (see below) was added to the organic component to re-extract any nucleic 
acids that might still be present. The sample was centrifuged again and the 
aqueous phase collected and pooled with first extraction. An equal volume of 
chloroform was added and the sample was centrifuged as before. The aqueous 
phase was collected and divided into two 2ml Eppendorf tubes.  
 
The DNA was precipitated by adding 1/10 volume of 3M sodium acetate pH 5.2 
and 2.5 volumes 100% ice-cold ethanol to the aqueous phases. Precipitation was 
aided by placing the solution at –70°C for 30 minutes. The solution was 
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centrifuged at 13000rpm for 20 minutes at 4°C. The pellet was washed in 70% 
ethanol and centrifuged again. The supernatant was removed and the pellet left to 
air-dry overnight. The pellet was finally resuspended in 30ul nuclease-free water.  
 
Lysis buffer pH 8.0 
40mM Tris-HCl  
80mM EDTA  
2% SDS 
0.1mg/ml Proteinase-K (add just before use) 
 
TE buffer pH 8.0 
10mM Tris-HCl  
1mM EDTA  
 
3M sodium acetate pH 5.2 
24.61g sodium acetate in a final volume of 100ml milliQ water, pH with 
NaOH 
2.2.2 Determining DNA concentration and purity 
DNA concentration was determined spectrophotometrically using a Beckman DU-
65 spectrophotometer. The absorbance of a 20x diluted sample of the DNA was 
read at a wavelength of 260nm. The following formula was used to calculate the 
concentration of the DNA sample: 
 
 
 
 
 
 
 
Readings taken at a wavelength of 280nm indicated the purity of the DNA by 
calculating the OD 260/280 ratio. A ratio of 1.8 indicates a pure sample, less than 
= Concentration (ug/ul) 
OD260 x extinction coefficient (E)* x dilution factor 
1000 
*1 OD260 unit of double stranded DNA = 50ug/ml 
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this indicates protein and/or phenol contamination and greater than 1.8 indicates 
RNA contamination. 
 
The DNA was also visualised on a 1% agarose gel. 0.5g agarose was added to 
50ml Tris-acetate-EDTA (TAE) buffer (see below) and dissolved by heating. 5ul 
of 10ug/ul ethidium bromide was added once the agarose had cooled slightly. The 
agarose was poured and left to set in a gel holder. The gel was transferred to a 
horizontal mini-gel chamber that had been filled with TAE buffer so that the gel 
was submerged. Between 1-5ul of DNA was mixed with 1ul Fermentas 
MassRuler loading dye solution and loaded into wells using a Gilson pipette. The 
Fermentas MassRuler™ High Range (or full range) DNA Ladder was used as a 
marker to indicate the DNA size according to the number of DNA base pairs. 10ul 
of 10ug/ul ethidium bromide was added to the buffer at the positive end of the gel 
chamber. The ethidium bromide intercalates in the double stranded DNA and 
fluoresces under UV light. Images of the gel were captured using a Syngene gel 
doc system. 
 
The concentration of DNA was estimated using the Syngene Tools on the 
Syngene gel doc system. These tools compare the intensity of the bands between 
the sample of DNA and the known concentrations of the Fermentas MassRuler™ 
High Range DNA Ladder. The purity of the DNA was determined by the absence 
of rRNA contamination in the gel and the integrity of DNA was assessed by a 
single band present in the gel as opposed to a smear due to degraded DNA.  
 
TAE Buffer pH 8.0 
40mM Tris-Acetate 
1mM EDTA 
 
  
Materials and Methods                                                                                           24 
2.3 PCR amplification of PfMyb2 
2.3.1 PCR conditions 
PCR primers were designed for cloning the 2700bp full length PfMyb2 gene into 
three expression vectors- pET-41a, pGEX-4T-2 and pTriEx-3. The forward 
sequence contained a BamH1 restriction site and the reverse sequence contained a 
Xho1 restriction site to facilitate directional cloning. The reverse primer was also 
designed to remove the stop codon of the gene to allow for a carboxyl his-tag to 
be added to the protein when the pET-41a and pTriEx-3 expression vectors were 
used. The pGEX-4T-2 expression vector attached an amino terminal glutathione-
S-tranferase (GST) protein tag to the recombinant protein.     
 
The primers were synthesized by Inqaba Biotech, made up to a 100uM stock in 
TE buffer, pH 8.0 (see section 2.2.1) and stored at –20°C. The sequences were as 
follows: 
PfMyb2wholeForward: 
5’GAATGGATCCATGAGGATTCAAATAAAAGGAGG3’ 
PfMyb2wholeReverse: 5’GGCGGCGGCCTCGAGTGGCACCTTTAACGT3’ 
The restriction enzyme sites are underlined (BamHI and XhoI for the forward and 
reverse primer respectively) and the bases flanking these sites were added to allow 
for the restriction enzyme to attach to the strand to allow for digestion. 
 
PCR conditions were optimised using the Promega master mix system but inserts 
for cloning were generated using the Eppendorf TripleMaster PCR system, which 
uses a high fidelity Taq polymerase to minimize errors during amplification. All 
reactions were set up on ice. The final reaction volume for both master mixes was 
50ul. The reactions contained the components seen in tables 2.3.1 and 2.3.2. The 
PCR conditions are listed in table 2.3.3. 
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Table 2.3.1: Components of the PCR reaction using the Promega Master Mix 
Components Amount for 1 reaction 
DNA 50ng 
2X Promega master mix 25ul 
Forward Primer (10uM) 1ul 
Reverse Primer (10uM) 1ul 
Nuclease free water Make up to final volume of 50ul 
Total 50ul 
  
Table 2.3.2: Components of the PCR reaction using the Eppendorf TripleMaster PCR 
system 
Components Amount for 1 reaction 
DNA 50ng 
10 X High fidelity buffer 5ul 
dNTPs (2.5mM each) 4ul 
Forward Primer (10uM) 1ul 
Reverse Primer (10uM) 1ul 
High Fidelity Taq polymerase 1ul 
Nuclease free water Make up to final volume of 50ul 
Total 50ul 
 
Table 2.3.3: Optimised PCR conditions for PfMy2 PCR 
 Temperature Time 
Initial Denaturation 94°C 2 min 
Primary Cycles 
Denaturation 94°C 1.5 min 
Annealing 56°C 1 min 
Extension 68°C 3 min 
Secondary Cycles 
Denaturation 94°C 1.5 min 
Annealing 50°C 1 min 
Extension 68°C 3 min 
 
X4 
X 36 
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PCR products were viewed on a 1% agarose gel as indicated in section 2.2.2. The 
size of the amplified gene was estimated against the Fermentas MassRuler™ High 
Range DNA Ladder. 
2.3.2 Phenol/chloroform purification of PCR product 
Once PCR amplification of the PfMyb2 gene was verified on an agarose gel the 
amplified gene was purified using phenol and chloroform. Four PCR reactions 
were pooled together to make up a volume of 200ul and to this 200ul 1:1 dilution 
of phenol/chloroform added. This was centrifuged on the desktop Eppendorf 
5415R centrifuge at 13000rpm for 5 minutes at 4°C and the aqueous phase 
collected. 50ul TE buffer was added to the organic phase to extract any DNA that 
might still be present. This was centrifuged as before and the aqueous phase 
collected and pooled with the previously collected aqueous phase. To this an 
equal volume of chloroform was added followed by centrifugation as before and 
collection of the aqueous phase. The DNA was precipitated as in section 2.2.1 and 
the DNA pellet was resuspended in 10ul nuclease free water. The concentration of 
the DNA was determined using the Beckman DU-65 spectrophotometer or 
electrophoresis in a 1% agarose gel as mentioned in section 2.2.2. 
 
2.4 Cloning PfMyb2 
2.4.1 Large-scale preparations of expression vectors 
Alkaline lysis was used to isolate plasmid DNA. This method involves denaturing 
the bacterial chromosomal DNA and plasmid DNA. The plasmid DNA is circular 
and therefore the two stands remain connected to one another and can renature 
rapidly. The chromosomal DNA becomes single stranded and does not renature 
effectively. It is removed with the rest of the cell debris as single stranded DNA is 
insoluble in high salt concentrations. 
 
Escherichi coli cells containing one of the Novagen expression vectors –pET-41a, 
pGEX-4T-2 and pTriEx-3 (appendix A-1, A-2 and A-5 for vector maps) were 
inoculated into 20ml Luria broth (LB) (see below) containing either 0.1mg/ml 
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kanamycin (for pET-41a) or 0.1mg/ml ampicillin (for pGEX-4T-2 and pTriEx-3) 
and left shaking at 37°C overnight. Cultures were centrifuged in the Beckman J2-
21 centrifuge using a JA-17 rotor at 10000rpm for 5 minutes at room temperature 
and the supernatant removed. The bacterial cells were resuspended in 1ml ice-cold 
lysis buffer (see below), vortexed and left to stand for 5 minutes at room 
temperature. Two ml of NaOH and SDS solution and 1.5ml of potassium acetate 
solution (see below) were added to the lysed bacteria. The solution was left on ice 
for 5 minutes then centrifuged at 13000rpm for 10 minutes at 4°C and the 
supernatants collected in six 2ml Eppendorf tubes. Each tube was filled to 
capacity with 100% ice-cold ethanol and left to stand at room temperature for 5 
minutes. These solutions were centrifuged in the Eppendorf desktop 5415R 
centrifuge at 13000rpm for 10 minutes at 4°C. The supernatants were removed 
and the plasmid DNA pellets left to air-dry for 30 minutes. Each pellet was then 
resuspended in 100ul TE buffer. One ul Fermentas Ribonuclease A (10mg/ml) 
was added to each tube and this was incubated in a water bath preheated to 37°C 
for 30 minutes. 300ul 5M potassium acetate and 500ul of a 1:1 dilution of 
phenol/chloroform were added to each tube and then centrifuged at 13000rpm for 
5 minutes at 4°C. The aqueous phase was collected and the DNA was precipitated 
as in section 2.2.1. The DNA pellets were resuspended in 20ul nuclease free 
water. 
 
The concentration of the DNA was determined using the Beckman DU-65 
spectrophotometer and the DNA was visualised on a 1% agarose gel as described 
in section 2.2.2. 
 
LB Medium 
10g NaCl 
10g BactoTMTryptone 
5g Yeast Extract 
10ml 1M Tris-HCl pH 7.5 
Made up in 1L milliQ water and autoclaved 
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Lysis Buffer 
50mM Glucose 
10mM EDTA 
25mM Tris-HCl pH 8.0 
 
NaOH and SDS solution 
500ul 0.4M NaOH  
100ul 10% SDS  
400ul milliQ water 
Made up just before use from stock solutions  
 
Potassium acetate solution 
2ml 5M CH3COOH  
1ml 5M CH3COOK  
Made up just before use from stock solutions 
 
TE Buffer 
10mM Tris-HCl pH 8 
1mM EDTA 
2.4.2 Enzyme digestion of PfMyb2 PCR product and vectors 
All expression vectors and the amplified full length PfMyb2 gene were digested 
with BamHI and XhoI to allow for site directed ligation of the gene into the 
vector. Two controls were set up with vector DNA, each one containing only one 
of the restriction enzymes to confirm that both enzymes were active. The reactions 
were set up using a final concentration of 2x Fermentas Tango™ buffer. 
According to the package insert of the enzymes, 2X Tango™ buffer is the optimal 
buffer for a double digest. Their activity in 2x Tango™ is 100% and 50-100% for 
BamHI and XhoI respectively. Restriction enzyme digestion was verified by 
electrophoresis of the vector DNA digestions on a 1% agarose gel, as the digested, 
linearised vector DNA would separate at a different size to undigested circular 
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vector DNA. The components of the enzyme digestion can be seen in table 
2.4.2.1. 
Table 2.4.2.1: The components of the restriction enzyme digestion  
Expression vector Components 
Experiment BamHI Control XhoI Control 
PfMyb2 
amplicon 
DNA 20ul 5ul 5ul 10ul 
Tango buffer™  (10X) 8ul 4ul 4ul 4ul 
BamHI (10U/ul) 1ul 1ul - 1ul 
XhoI (10U/ul) 1ul - 1ul 1ul 
Water 10ul 10ul 10ul 4ul 
Total 40ul 20ul 20ul 20ul 
   
After verification of digestion, the PfMyb2 amplicon and vector (that had been cut 
by both restriction enzymes) were made up to 200ul with nuclease free water and 
the DNA was purified using the phenol/chloroform method as performed in 
section 2.3.2. The concentrations of the DNA samples were estimated using the 
Beckman DU-65 spectrophotometer or by electrophoresis in a 1% agarose gel 
(both methods described in section 2.2.2).  
2.4.3 Ligation and subcloning of PfMyb2 into pET-41a and pGEX-4T-2  
Amplified PfMyb2 was cloned into the expression vectors using the Roche Rapid 
Ligation Kit. The amount of vector to be used (in ng) was determined by the 
concentration of the purified vector following restriction enzyme digestion. The 
ratio of vector to insert size was calculated using the following equation: 
 
 
 
 
The Roche Rapid Ligation Kit suggests that a 1:3 vector:insert molar ratio should 
be used for ligation. To calculate how much insert is needed (in ng) for the 
liagtion the following equation was used:   
 
 
 
Size of vector (Kb) 
Size of insert (Kb)      Ratio of vector to insert size (m)   = 
Amount of vector (ng) 
m 
Amount of insert required for a 1:3 ratio (ng)  = X3 
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No more than 200ng of total DNA was used per reaction. Ligation reactions were 
set up on ice and were then left at room temperature for 20 minutes. A control was 
set up with only vector and no insert to determine if re-ligation of vector occurred. 
The components of the ligation reaction are in table 2.4.3.1.  
 
Table 2.4.3.1: Components of the ligation reaction 
 Experiment Control 
Vector DNA xul xul 
Insert DNA yul - 
5X DNA Dilution buffer 4ul 4ul 
Water 6 - (x + y) ul 6-xul 
Sub-total 10ul 10ul 
2X T4 DNA Ligation Buffer 10ul 10ul 
T4 DNA ligase (5U/ul) 1ul 1ul 
Total 21ul 21ul 
 
2.4.4 Transformation of DH5α E.coli cells with pET-41a and pGEX-4T-2 
constructs 
Invitrogen DH5α E. coli bacterial cells were used for sub-cloning of the 
expression vector constructs. This strain contains no antibiotic resistance and 
acquires antibiotic resistance with the uptake of the expression vectors, which 
encode antibiotic resistance. Therefore transformed cells are selected under 
antibiotic stress.      
 
Transformation reactions were performed according to the protocol provided with 
the competent DH5α E. coli cells. For the control and experiments half of the 
ligation reaction (~100ng) was transferred to 50ul competent DH5α E. coli cells 
and placed on ice for 30 minutes. To induce uptake of the DNA the cells were 
heat-shocked at 37°C for 20 seconds in a pre-heated water bath and placed back 
on ice for 2 minutes. 450ul LB was added to the bacterial cells and they were 
incubated on a shaking platform at 37°C for 1 hour therefore allowing the cells to 
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grow under no antibiotic stress. The culture was plated in 50ul, 100ul and 300ul 
aliquots onto agar plates (see below) containing either 0.1mg/ml kanamycin or 
ampicillin, depending on the expression vector that was used for cloning. Plates 
were incubated at 37°C overnight.  
 
After transformation, if a similar number or more colonies grew on the control 
plate than on the experiment plate then it was assumed that the vector had re-
ligated and that the majority of the colonies on the experiment plate would also 
only contain empty vectors. If there were fewer colonies on the control plate, the 
colonies on the experiment plate were more likely to contain vector and insert and 
were screened for the PfMyb2 insert. 
 
Colonies that were present on the experiment plates were picked off and 
resuspended in 10ul sterile water. 2ml of LB containing 0.1mg/ml of the 
appropriate antibiotics (section 2.4.1) in sterile Falcon® 14ml Polypropylene 
round-bottom tubes was inoculated with 5ul of the resuspended colony. This was 
incubated on a shaking platform at 37°C overnight. To verify the presence of the 
PfMyb2 insert the remaining 5ul were analysed by PCR as described in section 
2.3.1 with either the PfMyb2-specific PCR primers or vector-specific primers.  
 
Glycerol stocks were made of the overnight cultures by combining 500ul sterile 
60% glycerol and 500ul of culture and storing at -70°C. Plasmid preparations 
were performed on the remaining 1.5ml overnight cultures using the Sigma 
GenElut™ plasmid miniprep kit. The concentration of plasmid DNA was 
determined using the Beckman DU-65 spectrophotometer or a 1% agarose gel as 
described in section 2.2.2. The plasmid DNA was used for a restriction enzyme 
digestion with BamHI and XhoI as described in section 2.4.2 to confirm the 
presence of the PfMyb2 insert. 
 
Agar plates 
200ml LB medium 
3g Agar 
0.1mg/ml specific antibiotics for each expression vector after autoclaving. 
  
Materials and Methods                                                                                           32 
Pour into sterile Petri dishes (8cm diameter) 
2.4.5 Sequencing of PfMyb2 insert 
Once it was verified that the pGEX-4T-2 and pET-41a vectors contained the 
PfMyb2 insert, plasmid preparations of the clones were sent to Inqaba Biotech for 
automated sequencing. Initially vector primers were used to sequence the insert 
from both the 5’ and 3’ end.  
 
Sequencing primers for pGEX-4T-2 bind to nucleotides 869-891 and 1041-1019 
for the 5’ and 3’ ends respectively (appendix A-3). The inserted gene would be 
located between nucleotides 930-966 in the multiple cloning site (MCS). The 
pET-41a T7 Promoter Primer and T7 Terminator Primer bind to regions up stream 
and down stream of the MCS respectively. This would also cause amplification of 
the MCS or the inserted gene fragment if ligation was successful. Three internal 
forward primers were designed, that would bind to three regions along the gene 
insert, which was approximately 2700bp and too large to sequence in one 
reaction. The internal primers were synthesized by Inqaba Biotech and their 
sequences were as follows: 
PfMyb2WholeSeq1F: 5'ACTTGCAAATACGAAAGG3' 
PfMyb2WholeSeq2F: 5'GATCTAAGTATACAACAAGCAG3' 
PfMyb2WholeSeq3F: 5'CCAGAATGTGATACGGAC3' 
These three primers bind along the PfMyb2 gene insert at nucleotides 465-482, 
1150-1171 and 1753-1770 respectively (appendix A-3).  
2.4.6 Ligation and subcloning of PfMyb2 into pTriEx-3 
The pGEX-4T-2-PfMyb2 constructs that had been sequenced were digested as 
described in section 2.4.2 to cut out the insert.  Electrophoresis on a 1% agarose 
gel of the digest sample separated the PfMyb2 insert from the rest of the vector. 
The PfMyb2 DNA bands were visualised on a UV trans-illuminator at a 
wavelength of 302nm and cut out of the gel using a sharp scalpel. The insert DNA 
was isolated from the gel using the Qiagen MiniElute Gel Extraction Kit. Ligation 
of the insert into the pTriEx-3 vector and transformation of DH5α E. coli cells 
were performed as described in sections 2.4.3 and 2.4.4. 
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2.4.7 Transformation of Rosetta 2(DE3) E. coli cells with expression vector 
constructs  
Novagen Rosetta 2(DE3) E. coli were the choice of bacterial cells used to produce 
recombinant protein as they contain a chloramphenicol-resistant plasmid 
(pRARE) encoding rare tRNAs (AUA, AGG, AGA, CUA, CCC and GGA) that 
are not usually expressed in E. coli and help enhance the expression of eukaryotic 
malaria parasite proteins.  
 
Rosetta 2(DE3) E. coli cells were transformed with the fully sequenced vector 
construct DNA obtained from the plasmid mini preparations. One hundred ng of 
plasmid DNA was added to 20ul competent Rosetta E. coli cells and left on ice for 
30 minutes. The cells were then heat shocked at 37°C for 20 seconds and placed 
back on ice for 2 minutes. The cells were plated directly onto agar containing 
0.1mg/ml of specific antibiotics (section 2.4.1) for the vector construct and 
0.05mg/ml chloramphenicol to select for Rosetta 2(DE3) E. coli cells containing 
pRARE. The plates were incubated at 37°C, overnight. Transformed cells were 
analysed in the same manner as described for transformation of DH5α E. coli 
cells in section 2.4.4.   
 
2.5 Expression of Recombinant PfMyb2 
2.5.1 Induction of protein expression  
2.5.1.1 Induction with Overnight Express™ Instant TB Medium  
10ul of the glycerol stocks of the transformed Rosetta 2(DE3) E. coli cells were 
used to inoculate 10ml LB containing 0.05mg/ml chloramphenicol and 0.1mg/ml 
of the appropriate antibiotics (section 2.4.1) for each expression vector. These 
cultures were grown overnight in autoclaved 50ml Erlenmeyer flasks on a shaking 
platform at 37°C. The absorbance of the cultures were read on the Beckman DU-
65 spectrophotometer at a wavelength of 600nm and an absorbance of greater than 
0.5 ensured that the cells had entered the log phase of growth. A control was also 
set up that contained the expression vector with no insert. The Novagen Overnight 
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Express™ Instant TB Medium (see below) was used as the medium of choice for 
autoinduction of cells to produce the recombinant protein. This system induces 
transcription of the cloned gene that is under control of a lac promoter. The 
medium components are metabolised and cause a build up of lactose, which in 
turn causes autoinduction of the lac promoter. 500ml of Overnight Express™ 
Instant TB Medium was inoculated with 10ml of the overnight log phase culture 
and this was divided into two autoclaved 1L Erlenmeyer flasks. Protein 
expression was induced at room temperature on a shaking platform for at least 18 
hours or until the absorbance of each of the cultures was greater than one at a 
wavelength of 600nm. The control containing only the expression vector was set 
up in the same manner. 
 
After induction the cultures were pooled and 1ml of the culture was removed and 
centrifuged in the Eppendorf desktop 5415R centrifuge at 13000rpm for 1 minute 
at room temperature. The bacterial pellet was resuspended in 200ul nuclease free 
water and this sample was used for total sample protein evaluation using SDS-
PAGE. The rest of the culture was transferred to two 250ml Beckman centrifuge 
tubes and centrifuged in the Beckman J2-21 using a JA-14 rotor at 5000rpm for 
10 minutes at room temperature. The supernatant was removed and the bacterial 
pellets were placed at -70°C for 20 minutes to aid bacterial cell lysis. Bacterial 
cells in each pellet were then lysed with 1ml Novagen BugBuster® containing 1ul 
Calbiochem Protease Inhibitor Cocktail Set III (details in table 2.5.1.1).  
 
Table 2.5.1.1: Protease inhibitors contained in the Calbiochem Protease Inhibitor Cocktail 
Set III.   
(www.merckbiosciences.co.uk/html/cbc/Protease_Inhibitor_Cocktail_Sets.htm) 
Product Concentration Target protease 
AEBSF, Hydrochloride 100mM Serine proteases 
Aprotinin, Bovine Lung, 
Lyophilized 
80uM Broad spectrum, serine proteases 
Bestatin 5mM Aminopeptidase B and leucine aminopeptidase 
E-64, Protease inhibitor 1.5mM Cysteine proteases 
Leupeptin, Hemisulfate 2mM Cysteine proteases and trypsin-like proteases 
Pepstatin A 1mM Aspartic proteases 
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The recommended amount of BugBuster® is 2.5ml per 50ml of culture but only 
1ml per 500ml culture was used so that the induced protein was as concentrated as 
possible. Incomplete lysis of the bacterial cells, due to the smaller volume of 
BugBuster® used, could occur but to prevent this the suspensions were gently 
agitated on a shaking platform for 1 hour at room temperature before being 
centrifuged in the Eppendorf desktop 5415R centrifuge at 13000rpm for 20 
minutes at 4°C. The soluble fraction of the samples (the supernatants) were 
collected and pooled and 150ul put aside for SDS-PAGE analysis. The rest of the 
soluble phase was stored at 4°C or -20°C for long term storage. As much of the 
insoluble fraction (pellet) as possible was resuspended in 300ul TE buffer and 
150ul collected for SDS-PAGE analysis. The rest of the insoluble fraction was 
stored at –20°C. The same procedure was carried out for the control sample.  
 
Overnight Express™ Instant TB Medium 
Overnight Express™ Instant TB Medium EasyPak (60g) 
10ml Glycerol 
Make up to 1L 
Autoclave and store at 4°C 
 
2.5.1.2 Induction with IPTG 
The induction of protein expression was also analysed using IPTG, which induces 
the utilisation of lactose and activation of the inserted gene under control of the 
lac promoter. The Rosetta E. coli stocks were grown overnight as described in 
section 2.5.1.1. 10ml of culture was used to inoculate 500ml TB medium 
containing various concentrations of IPTG ranging from 0.4-1mM (from a 100M 
IPTG stock made up in water and sterile filtered). Induction was performed at 
either 25°C or 37°C for various lengths of time ranging from 6 hours to 24 hours. 
Protein was extracted from these cultures as described in section 2.5.1.1.   
2.5.2 SDS-PAGE analysis 
Protein samples in 150ul aliquots from the total, soluble and insoluble fractions 
were mixed with 49ul of gel loading dye made up of 40ul 5X suspension solution 
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(see below), 4ul -mercaptoethanol and 5ul sucrose and dye solution (see below), 
which resulted in a final concentration of 2.5% -mercaptoethanol, 5% sucrose 
and 0.016% bromophenol blue. The samples were boiled for 3 minutes to 
denature the proteins. These samples were stored at 4°C for short-term storage or -
20°C for long-term storage. 
 
Protein samples were analysed on a 12% Laemmli gel (Laemmli, 1970) 
containing a 4% stacking gel. The gel was cast in a Hoefer Mighty Small™ SE 
245 dual gel caster and the gel was made up from the components in table 2.5.2.1. 
 
Table 2.5.2.1: Components of the Laemmli separating and stacking gels 
 12% Separating gel 4% Stacking gel 
30% Acrylamide 4ml 521ul 
1% Bis-acrylamide 1ml 400ul 
4X Lower Gel Buffer 2.5ml - 
4X Upper Gel Buffer - 1ml 
10%SDS 200ul 80ul 
Water 2.195ml 1.946ml 
10% Ammonium persulphate (made 
just before use) 
100ul 40ul 
TEMED 5ul 3ul 
Final volume 10ml 4ml 
 
The separating gel was poured between a 10cm X 8cm glass plate and notched 
aluminium plate that were separated with 1.5mm spacers and had been placed in 
the casting chamber. This was layered with isopropanol so that the gel surface was 
not exposed to oxygen, which ensured efficient cross-linking between the 
acrylamide and bis-acrylamide. The isopropanol was poured off after 30 minutes 
and the stacking gel was poured on top of the separating gel and a 12 well comb 
inserted at the top and left to set for 30 minutes. The gel was transferred to a 
vertical running chamber and the top and bottom chamber filled with running 
buffer (see below). Protein samples were loaded into the wells of the gel using a 
50ul Hamilton syringe. The Fermentas PageRuler™ prestained protein ladder or 
an erythrocyte membrane sample (extracted by Kubendran Naidoo) were also 
loaded into wells and were used to determine the molecular weights of the 
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proteins. The running chamber was connected to a Hoefer MightySlim SX 250 
power supply and the current set at 25mA. The gel was removed from the 
chamber after 1.5 hours, when the dye front would have reached the bottom of the 
gel, and placed in Coomassie Blue stain with gentle agitation on a shaker 
overnight. The gel was destained in a solution containing 10% acetic acid and 
10% methanol.  
 
5X suspension solution pH 8.0 
50mM Tris-HCL 
5mM EDTA 
5%SDS 
25% sucrose 
 
Sucrose and dye solution 
2.5% sucrose 
0.5% Bromophenol blue 
 
4X Lower gel buffer (LGB) pH 8.8 
1.5M Tris-HCl  
 
4X Upper gel buffer (UGB) pH 6.8 
500mM Tris-HCl  
 
Running buffer pH 8.5 
25mM Tris 
192mM Glycine  
1% SDS 
 
Coomassie Blue 
1g Coomassie Blue R-250 
500ml Isopropanol 
200ml Acetic acid 
Made up to 2L with milliQ water 
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2.5.3 Western blot analysis 
Proteins were electrophoresed on a Laemmli gel as described in section 2.5.2. The 
gel was not placed in Coomassie Blue stain as the proteins in the gel were 
transferred to a nitrocellulose membrane. The gel and water-soaked Amersham 
HyBond™-C Extra nitrocellulose membrane were placed between two sheets of 
Biorad extra thick filter paper and these were placed between two sponges, all of 
which had been soaked in transblot buffer (see below). This was secured in a 
cassette and transferred to a Hoefer TE series Transphor electrophoresis unit filled 
with ice-cold transblot buffer so that the cassette was immersed in the buffer. In 
the chamber the gel faced the cathode and the nitrocellulose membrane faced the 
anode. The transfer chamber was connected to BioRad model 200/2.0 power 
supply and set to 35V (0.08Amps) in the 4°C cold room and left overnight. The 
negatively charged proteins moved towards the positive anode and bound to the 
positive nitrocellulose membrane. 
  
The membrane was removed from the cassette and placed in TBS for 5 minutes. 
1ml Ponceau S  (see below) was added to the membrane to stain proteins and 
verify that they had been transferred from the gel to the membrane. The protein 
bands of the erythrocyte membrane were also marked out to indicate the 
molecular weight of the protein bands. Ponceau S stain was removed from the 
membrane as soon as the protein bands were visible by rinsing in milliQ water 
several times.  
 
Membranes containing recombinant proteins linked to GST were blocked in 30ml 
3% BSA in TBS (see below) for 1 hour and then washed three times in TBS for 5 
minutes per wash. The membrane was incubated in 30ml 1% BSA in TBS 
containing a 1:120000 Amersham goat anti GST antibody linked to horseradish 
peroxidase (HRP). This was agitated gently for 1 hour at room temperature.  The 
membrane was washed five times in TBS containing 0.05% Tween®-20 detergent 
for 5 minutes per wash and then in TBS only for 5 minutes. 
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Chemiluminescence detection was carried out in a dark room. The Pierce 
SuperSignal® West Pico Chemiluminescent Substrate Kit was used. The HRP 
attached to the antibodies, which were bound to the tag of the fusion PfMyb2 
protein, would cause fluorescence of the substrate. An X-ray film was exposed to 
the fluorescence revealing the presence of the fusion protein, PfMyb2. One ml of 
a 1:1 dilution of SuperSignal® West Pico Enhancer Solution and SuperSignal® 
West Pico Peroxide Solution were added to the membrane and left for 5 minutes. 
The solution was poured off and the blot was exposed to AGFA CP-G Plus 
medical X-ray film in a cassette for 2-5 minutes. The X-ray film was developed in 
1X Axim Medical X-ray developer until an image of the fluorescing protein bands 
was visualised. The film was fixed for 1 minute in 1X Perfix high speed X-ray 
fixer to stop further development of the signal.  
 
Transblot buffer (pH 8.3) 
25mM Tris 
192mM Glycine 
20% (v/v) Methanol 
  
Tris Buffered Saline (TBS) (pH 7.5) 
50mM Tris-HCl 
154mM NaCl 
 
Ponceau S 
0.1g Ponceau S 
700ul Glacial acetic acid 
9.3ml milliQ water 
 
2.6. Purification of recombinant PfMyb2 
2.6.1 Purification of inclusion bodies and refolding of insoluble protein 
The bacterial inclusion body purification and protein refolding techniques were 
adapted from Vallejo and Rinas (2004). This involves purifying the inclusion 
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bodies that contain the insoluble recombinant protein, denaturing the protein using 
guanidine hydrochloride followed by refolding of the protein by reducing the 
concentration of the guanidine hydrochloride. The refolding buffer contains a 
redox couple (reduced and oxidised glutathione) to facilitate the formation of 
native disulphide bonds and L-arginine to prevent aggregation.   
 
The insoluble pellets, containing bacterial inclusion bodies, obtained in section 
2.5.1 were resuspended in 2.5ml Novagen BugBuster™.  Merck L-Lysozyme was 
added to a final concentration of 1KU per millilitre and the solution left to stand 
for 5 minutes. Six volumes (15ml) of 1:10 dilution of BugBuster™ was added, the 
sample vortexed, then centrifuged in the Beckman J2-21 centrifuge using a JA-17 
rotor at 5000rpm for 15 minutes at 4°C. The supernatant was removed and the 
pellet resuspended in three volumes (7.5ml) of 1:10 dilution of BugBuster™ and 
centrifuged as before. This step was repeated four times, but on the final step the 
sample was centrifuged at 16000rpm and the pellet resuspended in 1ml denaturing 
buffer (see below). The sample was left to denature on a shaking platform, 
overnight at 4°C. The sample was centrifuged at 17000rpm for 20 minutes at 4°C 
in the Beckman J2-21 centrifuge using a JA-17 rotor and the supernatant, 
containing the denatured protein, was collected.  
 
The protein was refolded by diluting the guanidine hydrochloride with refolding 
buffer. 100ul of the denatured protein was used for protein refolding and the rest 
of the stock was stored at -20°C. The 100ul aliquot was diluted to bring the 
concentration of guanidine hydrochloride from 6M to 3M by adding 10ul 
refolding buffer (see below) to the sample every 5 minutes for 50 minutes, with a 
final volume of 200ul. The sample was divided into two aliquots of 100ul and 
placed into two Slide-A-Lyzer® mini dialysis units. The dialysis tubes were fitted 
into 2ml Eppendorf tubes containing 1.5ml refolding buffer, on ice and left for 5 
minutes. This process was repeated with fresh wash buffer, seven times, to 
remove as much of the guanidine hydrochloride without precipitating the protein. 
The dialysed samples were pooled and centrifuged in the Eppendorf desktop 
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5415R centrifuge at 13000rpm for 10 minutes and the supernatant collected. This 
fraction was used for affinity purification of the recombinant PfMyb2. 
 
Denaturing buffer 
6M guanidine hydrochloride 
50mM Tris-HCl pH 8 
10mM DTT 
100mM NaCl 
10mM EDTA 
 
Refolding buffer 
200mM Tris-HCl pH 8.0 
10mM EDTA 
1M L-arginine 
0.1mM PMFS (400mM stock made up in  DMSO, added gradually to the 
aqueous solution) 
2mM reduced glutathione 
0.2mM oxidised glutathione 
 
2.6.2 Affinity purification of the GST-linked recombinant PfMyb2  
2.6.2.1 Affinity purification of PfMyb2-GST from the soluble protein fraction 
The soluble protein fractions (~2ml) (section 2.5.1) were added to 10ul Promega 
MagneGST™ Glutathione particles that had been washed five times, 1 minute per 
wash, in 200ul GST wash buffer (see below) and resuspended in 10ul GST wash 
buffer. The suspension was agitated overnight on a shaking platform at 4°C. The 
magnetic beads were separated from the rest of the solution using a particle 
separator and the unbound fraction was removed. The beads were washed five 
times with GST wash buffer. During the first 2 washes the wash buffer was 
incubated with the beads for 5 minutes and for the rest of the washes the beads 
were quickly rinsed in GST wash buffer and the buffer removed. The GST-bound 
recombinant PfMyb2 was eluted with elution buffers containing 100mM 
glutathione or 200mM glutathione (see below) to deduce which concentration 
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resulted in the highest yield of protein. The sample was incubated with 60ul of 
either elution buffer for 1 hour while agitating on a shaking platform at 4°C, 
keeping the beads suspended for the full hour. This was repeated for a second 
elution but for only 15 minutes and the beads were finally stripped with 200ul 
GST-wash buffer containing 1% SDS. The eluted protein samples were analysed 
by SDS-PAGE and western blots (sections 2.5.2 and 2.5.3).  
2.6.2.2 Affinity purification of refolded PfMyb2  
The refolded protein obtained in section 2.6.1 was affinity purified as in section 
2.6.2.1. The final volume of refolded protein was added to 10ul glutathione 
particles and eluted as in section 2.6.2.1 but the second elution buffers contained 
1% Tween®-20 detergent. The eluted protein samples were analysed as in 
sections 2.5.2, 2.5.3. The final yield of protein was estimated, using the Laemmli 
gels, by comparing the intensity of the refolded protein band to the known 
concentrations of the protein bands of the Fermentas protein ladder.  
 
GST-wash buffer 
4.2mM Na2HPO4 
2mM K2HPO4 
140mM NaCl 
10mM KCl 
  
Glutathione elution buffer 
100mM Glutathione (pH with NaOH to between 7.0-8.0)  
or 
200mM Glutathione (pH with NaOH to between 7.0-8.0) 
50mM Tris-HCl (pH 8.1) 
 
Glutathione elution buffer (for the second elution of refolded proteins) 
100mM Glutathione (pH with NaOH to between 7.0-8.0) 
or 
200mM Glutathione (pH with NaOH to between 7.0-8.0) 
50mM Tris-HCl (pH 8.1) 
1% Tween®-20 detergent 
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2.7 Bioinformatic analysis of PfMyb2 
The Plasmodium genome database (PlasmoDB version 5.4) was used to 
summarise predicted characteristics of PfMyb2 such as gene and protein size, 
protein characteristics and expression profiles of the protein in the parasite. 
Hydropathy plots were calculated using the following website: 
http://www.vivo.colostate.edu/molkit/hydropathy/index.html, which used the 
Kyte-Doolittle scale to determine hydrophobic regions of the protein. Secondary 
structure predictions were performed on SCRATCH, using SS pro at the 
following website: www.igb.uci.edu/tools/scratch/. Basic Local Alignment Search 
Tool for proteins (BLASTP) searches were done to find homologous proteins to 
PfMyb2 while the European Molecular Biology Open Software Suite (EMBOSS) 
tools were used to calculate identity and similarity percentages between these 
proteins and perform multiple alignments. These tools included the pairwise 
alignment algorithms and ClustalW2 available at the following respective 
websites: www.ebi.ac.uk/emboss/align/index.html and 
www.ebi.ac.uk/Tools/clustalw2/. The recombinant proteins molecular weight and 
extinction co-efficients were determined using Expert Protein Analysis System 
(ExPASy) ProtParam tool (http://au.expasy.org/tools/protparam.html). 
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3. RESULTS 
3.1 DNA Extraction 
DNA was extracted from P. falciparum cultures that contained parasites in mainly 
the late trophozoite stage with over 10% parasitaemia (see figure 3.1 for a mixed 
parasite culture blood smear). The total yield of DNA per 30ml parasite culture 
ranged from 2.7ug to 18.9ug and the concentrations of the DNA were 0.09ug/ul to 
0.63ug/ul. The purity of the samples had OD260/280 ratios between 1.2 and 1.9, 
with the low ratio implying protein or phenol contamination. An example of a 
DNA extraction can be seen in figure 3.2. Samples with a high yield and a purity 
ratio close to 1.8 were used to amplify the PfMyb2 gene during PCR. 
 
 
Trophozoite
Rings
Schizonts
 
 
Figure 3.1: Mixed parasite culture 
Blood smear, stained with Rapindiff staining kit, of a mixed parasite culture containing 
trophozoite, ring and schizont stages of the intraerythrocytic lifecycle. The image was captured 
under oil immersion at 1000x magnification.  
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Figure 3.2: P. falciparum DNA extraction 
A 1% agarose gel showing 1ul of a total of 30ul extracted P. falciparum DNA (first lane) next to 
5ul Fermentas High Range MassRuler™. The chromosomal DNA has a high molecular weight 
and does not migrate as far as the marker in the gel.  
The single band in the gel indicates that the DNA is not degraded. 
 
 
3.2. PCR amplification of PfMyb2 
3.2.1 Optimisation of annealing temperatures for PCR segments 
The PCR used to amplify the PfMyb2 gene consisted of two segments, since the 
5’ restriction enzyme sites were not complementary to the PfMyb2 gene but were 
incorporated into the PfMyb2 PCR primers to allow directional cloning of the 
insert into the expression vectors. The first segment had four cycles and a low 
annealing temperature to allow the primers to pair up with complimentary bases 
on the PfMyb2 gene. The second segment had 34 cycles and a higher annealing 
temperature since the first four cycles would have generated a sequence that 
would contain the restriction enzyme sites and therefore the primers were fully 
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complimentary and would have a higher melting temperature. The optimisation of 
the annealing temperatures was performed using the Promega master mix. 
 
The two primers, PfMyb2wholeForward and PfMyb2wholeReverse, were 
designed using Gene Runner, version 3.05. These had calculated melting 
temperatures that were quite far apart at 65.9°C and 75.6°C respectively. This 
variation was due to the 5’ flanking bases that were added to incorporate the 
restriction enzyme site as well as additional bases to allow the enzyme to bind to 
the fragment during digestion. PfMyb2wholeReverse was unusual as it had only 
15bp complimentary to the PfMyb2 gene sequence. This design was decided upon 
as a longer primer was predicted (by Gene Runner) to form two possible hairpins 
which may have affected its efficacy during PCR. The additional 5’ flanking 
region required more base pairs for the XhoI restriction enzyme site than for 
BamHI site. Temperatures for both the primary and secondary annealing step were 
analysed from 50°C to 64°C. The best yield of pure PfMyb2 amplicon was 
obtained when the primary and secondary annealing temperatures were 56°C and 
50°C respectively, even though the secondary temperature was lower than the 
primary temperature (figure 3.2.1). These PCR conditions were decided on after 
setting up a gradient of temperatures (using the calculated melting temperatures as 
a guideline) on the Eppendorf gradient cycler machine that uses a range of 
primary and secondary annealing temperatures.    
 
3.2.2 Optimisation of amount of DNA used for PCR 
During optimisation of the annealing temperatures it was noted that the amount of 
DNA used in each PCR also had an influence on product yield and PCR success. 
Therefore while optimising the conditions for PCR, the reactions were set up with 
different amounts of DNA. 50ul Promega PCR reactions were set up with 50ng, 
200ng and 500ng of DNA (figure 3.2.2). The reaction tube with 50ng DNA 
resulted in PfMyb2 gene amplification while the other reactions only showed 
amplification of primer dimers. Therefore 50ng of DNA was used per reaction. 
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Figure 3.2.1: Optimisation of annealing temperatures for PfMyb2 PCR  
The 1% agarose gel shows an example of the PCR results to amplify the PfMyb2 gene using 
different primary annealing temperatures. The fragment length of the PfMyb2 gene is 2748bp. 
Amplification of the PfMyb2 gene was optimal when the primary and secondary annealing 
temperatures were 56°C and 50°C respectively, as seen in the first lane of the gel. 
Amplification did not occur when higher primary annealing temperatures were used and this may 
be due to failed PCR as it is also noted that no primer dimers are seen in these lanes.  
10ul of each reaction was loaded per well and 5ul of the Fermentas full range MassRuler™ was 
used as the marker. 
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Figure 3.2.2: Optimisation of DNA concentration per PCR reaction 
The 1% agarose gel shows that 50ng of P. falciparum DNA was optimal for PCR amplification of 
the PfMyb2 gene as seen in the first lane. The other lanes only showed primer dimer amplification. 
Irrelevant lanes of the gel have been excluded. 
10ul of each reaction was loaded per well and 5ul of the Fermentas full range MassRuler™ was 
used as the marker. 
 
Once the PCR conditions had been optimised, the PfMyb2 fragment was 
generated (using the high fidelity Taq polymerase system to minimise errors) so 
that it could be cloned into plasmid DNA and expressed in bacteria. 
 
3.3 Cloning of PfMyb2 into pET-41a 
The pET-41a system adds a carboxyl terminus his tag to the inserted gene 
resulting in a his-tagged recombinant protein (appendix A-1 for vector map). 
Numerous attempts were made to clone PfMyb2 into the pET-41a expression 
system without success. Restriction enzyme digest controls confirmed that both 
BamHI and XhoI were active and therefore the vector and gene insert were cut as 
seen in figure 3.3.1. Although the double digest of the vector only shows one band 
at 5933bp, corresponding to linearised pET-41a, there must still have been a small 
amount of undigested/incompletely digested vector present that was not sufficient 
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to be visualised in an agarose gel as the vector appeared to be religating after 
transformation of E. coli cells. On one occasion three colonies grew on one of the 
experiment plates but these contained no gene insert as seen in figure 3.3.2.  No 
further attempts were made to clone into pET-41a. 
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Figure 3.3.1: The pET-41a vector and PfMyb2 gene insert digested with BamHI and XhoI for 
cloning 
The 1% agarose gel shows the PfMyb2 gene insert and pET-41a vector in the first and second 
lanes respectively, both of which were digested with BamHI and XhoI to facilitate directional 
cloning into pET-41a. 
Digest controls, set up using only one restriction enzyme and vector DNA, can be seen in the last 
two lanes and indicate that the vector had been linearised to produce a single band of the expected 
size. Undigested vector is not shown. 
1ul of the PfMyb2 insert and pET-41a vector, both digested with restriction enzymes, were loaded 
and 5ul of each restriction enzyme control digest was loaded per well. 5ul of the Fermentas high 
range MassRuler™ was used as the marker. 
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Figure 3.3.2: Digested pET-41a plasmid constructs 
The 1% agarose gel shows the three pET-41a plasmid constructs digested with BamHI and XhoI. 
None of the constructs contained the PfMyb2 gene insert as no DNA was detected at 2748bp and 
the linearised construct migrated near to 6000bp, which is very close to 5933bp – the size of the 
pET-41a vector. Therefore the constructs represented re-ligated vector. 
10ul of each digest was loaded per well and 5ul of the Fermentas high range MassRuler™ was 
used as the marker. 
 
3.4. Cloning and expression of pGEX-4T-2-PfMyb2 constructs  
The pGEX-4T-2 expression system encodes a GST tag that is attached to the 
amino terminal of the fusion protein, PfMyb2-GST (appendix A-2, A-3 and A-4 
for vector map, gene sequence and fusion protein).  
3.4.1 Cloning of PfMyb2 into pGEX–4T-2 
PfMyb2 was successfully ligated into pGEX-4T-2 and DH5α E. coli bacterial 
cells were transformed with the plasmid constructs. The vector and insert, used in 
the ligation reaction, can be seen in figure 3.4.1.1. Experiment agar plates that had 
been spread with 300ul and 100ul of the transformation reaction contained 15 and 
10 colonies respectively. The control agar plate that had been spread with 300ul 
had 5 colonies, indicating that some of the plasmid had religated. 11 colonies 
were picked off the experiment plates and analysed by an initial PCR screen, 
using vector primers. Four of these colonies were positive for the PfMyb2 gene 
insert (figure 3.4.1.2) and these constructs were named pGEX2:2, pGEX2:3, 
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pGEX2:4 and pGEX2:6 after the order they had been taken from the plates. 
Restriction enzyme digestions on the plasmid preparations from the positive 
colonies verified the presence of the gene insert (figure 3.4.1.3)  
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Figure 3.4.1.1: The pGEX-4T-2 vector and PfMyb2 gene insert digested with BamHI and 
XhoI for cloning 
The 1% agarose gel shows the PfMyb2 gene insert and pGEX-4T-2 vector digested with the 
restriction enzymes BamHI and XhoI to facilitate directional cloning into the vector. 
5ul of the PfMyb2 insert and pET-41a vector, both digested with restriction enzymes, were loaded 
per well. 5ul of the Fermentas high range MassRuler™ was used as the marker. 
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Figure 3.4.1.2: PCR amplification of pGEX-4T-2 transformed DH5 E. coli colonies 
The 1% agarose gel shows the PCR amplification of the 11 colonies picked from the experiment 
plates after cloning into pGEX-4T-2.  
The only colonies that were positive for the PfMyb2 gene insert were 2,3,4 and 6. The smaller 
bands seen at the bottom of the gel are the amplified multiple cloning site (MCS) (~150bp) of 
pGEX-4T-2. The MCS was amplified as the primers used to screen the pGEX-4T-2-PfMyb2 
constructs were specific for the vector.  
The third colony is positive for both the gene insert and a MCS and it was thought that two 
colonies may have been picked off the agar plate.  
The size difference in the amplified MCS of some of the colonies cannot be explained. 
10ul of each reaction was loaded per well and 5ul of the Fermentas high range MassRuler™ was 
used as the marker. 
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Figure 3.4.1.3: The pGEX-4T-2-PfMyb2 constructs, digested with BamHI and XhoI, from 
transformed DH5 E. coli cells 
The 1% agarose gel shows the pGEX-4T-2-PfMyb2 constructs, digested with BamHI and XhoI, 
that were positive for the PfMyb2 gene during the PCR screening.  
The vector can be seen at 4900bp and the PfMyb2 insert at 2748bp, which confirms the PCR 
screening results. 
20ul of each digest was loaded per well and 5ul of the Fermentas high range MassRuler™ was 
used as the marker. 
 
3.4.2 Induction of PfMyb2-GST fusion protein in Rosetta E. coli 
Rosetta E. coli cells were transformed successfully with each of these pGEX-4T-
2-PfMyb2 constructs. One colony from each plate containing either the pGEX2:2, 
pGEX2:3, pGEX2:4 or pGEX2:6 constructs was picked off and analysed for the 
gene insert by PCR, using the PfMyb2 primers. The presence of the gene insert 
was verified with plasmid preparations and restriction enzyme digestions of these 
transformants (results not shown). 
 
The pGEX2:2, pGEX2:3 and pGEX2:6 constructs were induced to produce 
recombinant PfMyb2, fused to GST at the amino terminal end of the protein. The 
total and soluble protein fractions were analysed on Laemmli gels and Western 
blots. The expected molecular weight of the fusion protein was 134kDa (appendix 
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A-4) but it was not clear on the Laemmli gel whether the recombinant protein was 
being expressed, as there were E. coli proteins that also migrated between 170kDa 
and 130kDa. A Western blot detected the recombinant PfMyb2-GST at 134kDa in 
the protein fractions from E. coli cells containing the pGEX2:2 and pGEX2:3 
constructs, as seen in figure 3.4.2.1. The pGEX2:6 construct was positive for GST 
but at a lower molecular weight than the fusion protein. The band had a very 
similar molecular weight to the GST control. Therefore this construct presumably 
contained a mutation in the gene insert, resulting in a truncated protein or only the 
expression of the GST tag. The protein was soluble which further indicates that it 
is likely to be GST. No further studies were performed on pGEX2:6. Sequencing 
of pGEX2:4 was problematic and therefore this construct was not analysed for 
protein expression.   
 
Initial sequencing of the insert was performed using vector specific primers, 
however, due to the large size of the gene insert internal forward primers were 
designed to sequence the full length of the PfMyb2 gene insert (appendix A-3 and 
A-8). The DNA sequencing results for pGEX2:2 confirmed that the sequence of 
the amplified PfMyb2 gene was correct. Since it had been determined that this 
construct was expressing PfMyb2-GST in Rosetta E. coli cells, further 
experiments were performed on this construct only. The protein fractions of 
induced Rosetta E. coli cells containing pGEX2:2 were compared to induced 
Rosetta E. coli cells containing pGEX-4T-2 vector only. Induction of PfMyb2-
GST was tested with two induction media, LB containing IPTG and Overnight 
Express™ Instant TB Medium. Various conditions were tested including different 
concentrations of IPTG, induction temperatures and the length of time of 
induction. These variables were altered individually and together but resulted in 
very little protein expression each time (results not shown). The best induction 
results were achieved using Overnight Express™ Instant TB Medium, however 
most of the recombinant protein was in the insoluble fraction (figure 3.4.2.2). 
With each induction a faint protein band was visible at 134kDa in the total and 
insoluble fractions but was not as intense in the soluble fraction. This protein band 
was not seen in the soluble fraction of induced Rosetta E. coli containing pGEX-
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4T-2 only. However, other E. coli proteins could migrate at a similar molecular 
weight to the fusion protein so Western blots (figure 3.4.2.3) were performed to 
confirm the presence of PfMyb2-GST. The total and insoluble fractions were 
positive for GST at 134kDa for all inductions, while the soluble fraction was not 
always positive reflecting a variable yield of fusion protein. Even when a smaller 
volume of BugBuster® was used to lyse the cells and concentrate any soluble 
fusion protein, the recombinant protein could still not be detected consistently in 
the soluble fraction. 
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Figure 3.4.2.1: Western blot of PfMyb2-GST protein expressed from three of the pGEX-4T-
2-PfMyb2 constructs 
A Western blot to detect PfMyb2-GST at 134kDa using anti GST-HRP conjugate. The fusion 
protein was detected in the total fractions of E. coli containing constructs pGEX2:2 and pGEX2:3 
but not in the soluble fractions.  
Faint signals below the fusion protein were also detected in the total fractions. This may be due to 
truncated protein being expressed, as the GST is attached to the amino terminal end of the protein. 
It may also be non specific binding of the anti GST-HRP conjugate to E. coli proteins. 
E. coli containing the pGEX2:6 construct expressed a protein tagged with GST at a much lower 
molecular weight than 134kDa. This protein migrated at the same level as the GST control and 
therefore the insert presumably contained a mutation resulting in expression of the GST tag only. 
Protein bands of the Fermentas prestained protein ladder have been marked off and placed next to 
the blot, as the GST-HRP conjugate did not detect the protein markers. 
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Figure 3.4.2.2: Laemmli gel of induced Rosetta E. coli containing either pGEX2:2 or pGEX-
4T-2  
A: The Laemmli gel shows the pGEX-4T-2 soluble fraction (10ul/2ml) and total (5ul/1ml), 
insoluble (10ul/300ul) and soluble (15ul/2ml) fractions of induced Rosetta E coli containing 
pGEX2:2. 
B: Enlargement of the region where PfMyb2-GST should occur (highlighted with a black box). 
There is much less protein loaded in the total pGEX2:2 fraction than the other fractions. Even with 
such a small amount of protein in the total fraction there is a band at 134kDa (presumably 
PfMyb2-GST) that is also present in the insoluble fraction but absent from the soluble fraction of 
pGEX2:2. This band is also absent in the soluble pGEX-4T-2 fraction.  
Irrelevant lanes of the gel have been excluded. 
5ul of the Fermentas prestained protein ladder was used as the marker. 
A: 
B: 
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Figure 3.4.2.3: Western blot of soluble and insoluble fractions of Rosetta E. coli expressing 
the pGEX2:2 construct 
A Western blot to detect PfMyb2-GST using anti GST-HRP conjugate. 10ul/300ul of the insoluble 
fraction was loaded while 15ul/2ml, 25ul/2ml and 40ul/2ml of the soluble fraction were loaded.  
There are large amounts of PfMyb2-GST in the insoluble fraction compared to the amount of 
soluble PfMyb2-GST.  
The GST control also serves as an E. coli control (20ul/2ml soluble fraction loaded). The band 
above GST between molecular weights of ~30kDa - 50kDa may indicate non-specific binding of 
the anti-GST antibody to E. coli proteins as these bands are present in all fractions.  
The higher molecular weight bands (> ~50kDa) are presumably truncated forms of PfMyb2-GST 
as they are not present in the E. coli control fraction.  
Protein bands of the Fermentas prestained protein ladder have been marked off and placed next to 
the blot, as the GST-HRP conjugate did not detect the protein markers. 
 
Affinity purification of the soluble fraction using MagneGST™ Glutathione 
particles showed that no protein was eluted with elution buffer containing either 
100mM or 200mM glutathione. The absence of protein was due to a lack of 
starting material and not due to ineffective elution as no protein was detected 
when the glutathione particles were stripped (results not shown).  
 
As very little soluble PfMyb2-GST was expressed, the insoluble fusion protein 
from the bacterial inclusion bodies was extracted and denatured in guanidine 
hydrochloride. After denaturation, the guanidine hydrochloride concentration was 
decreased through dialysis and the protein refolded. The refolded fusion protein 
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was purified using 5ul of the MagneGST™ Glutathione particles and eluted in 
60ul elution buffer with 50mM glutathione.  
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Figure 3.4.2.4: Laemmli gel of refolded PfMyb2-GST 
The Laemmli gel shows the results of refolding the 134kDa PfMyb2-GST fusion protein and 
elution with 50mM glutathione.  
Protein bands at 134kDa can be seen in all the protein fractions, however the bands are very faint 
in the eluted samples.  
30ul/60ul of the elution and 30ul/200ul stripped particle fraction were loaded per well and 
20ul/200ul of the unbound and wash fractions were loaded per well. 5ul of erythrocyte membrane 
proteins was loaded as a molecular weight marker. 
 
When the samples were analysed by SDS-PAGE very faint protein bands were 
seen in the eluted fractions at ~134kDa (figure 3.4.2.4). Protein bands were also 
seen at this molecular weight in the unbound and stripped particle fractions. The 
western blots on these samples, however, were only positive for GST at ~134kDa 
in the stripped particle fraction (figure 3.4.2.5). This implied that the elution of the 
~134k a 
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protein was not effective and that it remained bound to the glutathione particles. 
Therefore varying elution conditions were tested, including the use of a non-ionic 
detergent. 
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Figure 3.4.2.5: Western blot of refolded PfMyb2-GST 
A Western blot using anti-GST HRP conjugate shows that PfMyb2-GST was not eluted with 
50mM glutathione but was still bound to the MagneGST™ Glutathione particles as the only 
detection of GST was at 134kDa in the stripped particle fraction.  
20ul/200ul of the unbound fraction and 30ul/60ul of the elution and 30ul/200ul stripped particle 
fraction were loaded per well. Protein bands of the Fermentas prestained protein ladder have been 
marked off and placed next to the blot, as the GST-HRP conjugate did not detect the markers. 
 
The glutathione concentration was increased and the protein was eluted in buffer 
containing 100mM or 200mM glutathione. A second elution was performed on 
the same sample using the same concentrations of glutathione and 1% Tween®-20 
detergent. The eluted samples were analysed on a Laemmli gel (figure 3.4.2.6). 
Protein bands were present at ~134kDa when the elution buffer contained a final 
concentration of 100mM and 200mM glutathione, but not in the secondary 
elutions. Elution was inefficient since protein bands at ~134kDa were still present 
when the beads had been stripped with SDS. These results were confirmed with a 
Western blot, figure 3.4.2.7, with the most intense signal detected when the 
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elution buffer had a final concentration of 200mM glutathione. The final yield of 
protein was estimated from the Laemmli gel by comparing the PfMyb2-GST 
protein band with the Fermantas prestained protein ladder that had a known 
concentration. There appeared to be ~1-2ug of PfMyb2-GST on the gel and 
therefore ~2-4ug per elution of refolded protein. This would result in a yield of 
~20-40ug PfMyb2-GST per 500ml E. coli culture.   
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Figure 3.4.2.6: Laemmli gel of refolded PfMyb2-GST using varying elution conditions 
The Laemmli gel shows the eluted, refolded PfMyb2-GST using different elution conditions in 
two experiments. Protein bands can be seen when the elution buffer contained 100mM and 
200mM glutathione. No bands were detected when the elution buffers contained 1% Tween®-20. 
30ul/60ul of the elution sample was loaded per lane. Protein bands can also be seen in the stripped 
particle fractions (40ul/200ul per lane).  
There is a band at the correct size (134kDa) of PfMyb2-GST and the lower molecular weight 
bands may be truncated forms of the fusion protein or E.coli proteins. 5ul of the Fermentas 
unstained protein ladder and 5ul of an erythrocyte membrane were loaded as molecular weight 
markers. 
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Figure 3.4.2.7: Western blot of refolded PfMyb2-GST using varying elution conditions 
The Western blot using anti-GST HRP conjugate shows the eluted, refolded PfMyb2-GST using 
different elution conditions. 
A signal at 134kDa was detected when the elution buffer contained 100mM and 200mM 
glutathione and when the particles were stripped. No signal was detected when Tween-20 was 
added to the elution buffer. GST was also detected in various bands that are smaller than the 
PfMyb2-GST fusion protein, which may be due to truncated proteins or degradation.  
20ul/200ul of the wash fractions, 40ul/200ul of the stripped particle fractions, and 30ul/60ul of the 
eluted sample were loaded. Protein bands of the Fermentas prestained protein ladder have been 
marked off and placed next to the blot, as the GST-HRP conjugate did not detect the markers. 
 
3.5. Cloning of PfMyb2 into pTriEx-3 
The yield of soluble PfMyb2-GST from the pGEX-PfMyb2 constructs was very 
low and the purification using glutathione-linked magnetic beads was inefficient 
and yielded minute amounts of protein, which prompted the use of the pTriEx-3 
expression vector. This vector encodes a his tag that is attached to the carboxyl 
end of the fusion protein (appendix A-5 and A-6) and purification of PfMyb2-his, 
using nickel coated beads may have been more successful. This vector can also be 
used to express recombinant proteins in mammalian and insect cell lines, as well 
as in E. coli.  
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3.5.1 Cloning into pTriEx-3 
The pGEX-4T-2 and pTriEx-3 vectors both have BamHI and XhoI restriction 
enzyme sites in the same orientation. Therefore the fully sequenced PfMyb2 gene 
insert was successfully cut out from pGEX2:2 and ligated into the pTriEx-3 vector 
which was used to transform DH5α E. coli cells. Religation of the vector did 
occur as the control plate contained 33 colonies and the experiment plate 
contained 45 colonies. 10 colonies from the experiment plates were chosen and 
screened for the PfMyb2 gene using PCR and PfMyb2 primers.  PCR screening 
revealed that only two out of the 10 colonies were positive for the gene insert, as 
seen in figure 3.5.1.1. These two pTriEx-3-PfMyb2 constructs were named 
pTriEx-3:5 and pTriEx-3:8 after the order they had been picked from the agar 
plate. Plasmid preparations and restriction enzyme digestion with BamHI and 
XhoI verified that these constructs contained the gene insert (figure 3.5.1.2). The 
plasmid preparations were used to transform Rosetta E. coli bacterial cells and the 
presence of the gene insert was verified as described above.  
3.5.2 Induction of pTriEx-PfMyb2 constructs 
Prior to inducing PfMyb2-his protein the vector sequence was scrutinised more 
closely, which revealed that the BamHI site was unfortunately not in frame with 
the vector initiation codon. This would create a premature stop codon at the first 
amino acid of PfMyb2 (appendix A-7) and no recombinant protein would be 
expressed which was confirmed by an induction experiment (results not shown).   
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Figure 3.5.1.1: PCR amplification of pTriEx-3 transformed DH5 E. coli colonies 
The 1% agarose gel shows PCR amplification of PfMyb2 insert from 10 colonies using PfMyb2 
specific primers. 
Only colonies 5 and 8 were positive for the 2748bp PfMyb2 amplicon. 
10ul of each reaction tube was loaded per well and 5ul of the Fermentas high range MassRuler™ 
was used as the marker. 
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Figure 3.5.1.2: Restriction enzyme digest of pTriEx-3-PfMyb2 constructs 
The 1% agarose gel shows the pTriEx-3-PfMyb2 constructs, digested with BamHI and XhoI.  
The vector can be seen at 5082bp and the PfMyb2 insert at 2748bp for both constructs. 
20ul of each digest was loaded per well and 5ul of the Fermentas high range MassRuler™ used as 
the marker. 
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3.6 Bioinformatic analysis of PfMyb2 
3.6.1 General features of PfMyb2 
The gene (Pf10_0327) is located on chromosome 10 and has only one exon of 
2748bp, which encodes 915 amino acids (see figure 3.6.1). PfMyb2 contains two 
Myb-like DNA-binding domains, which fall between residues 7-53 (R1) and 59-
103 (R2). These domains have homology to the R1 and R2 domains of PfMyb1. 
Seven low complexity regions are found throughout the protein but only one 
(KTEWNKEEEEKLLHLAKL) falls in part of the R2 domain, as it is located 
between residues 59-76. This low complexity region does not appear to be 
specific to P. falciparum as it is also found in Myb2 proteins of other Plasmodium 
species and in human cell division cycle 5 (CDC5), a homologue of PfMyb2. 
Hydropathy plots revealed that the protein is mainly hydrophilic with no 
transmembrane domain and secondary structure predictions showed mainly 
helices.  
 
 
 
Figure 3.6.1: Bioinformatic predictions of PfMyb2  
Annotation of PfMyb2 taken from PlasmoDB, version 5.4. 
The protein contains two amino-terminal, Myb-like DNA-binding domains. A Kyte-Doolittle 
hydropathy plot revealed that the protein is mainly hydrophilic as most regions of the protein in 
the plot fall below 0. Secondary structure predictions show mainly helices. One low complexity 
region out of seven falls within the second Myb-like DNA binding domain. 
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Expression studies by Le Roch et al. (2003) and by Bozdech et al (2003) have 
been summarised on PlasmoDB. These studies revealed that PfMyb2 mRNA is 
expressed throughout the intraerythracytic lifecycle (figure 3.6.2). Le Roch et al 
(2003) showed that temperature-synchronised and sorbitol-synchronised cultures 
have the highest mRNA expression at late ring and early ring stages respectively 
and the lowest expression level occurred in the late schizont stage. Work done by 
Florens et al (2004) which analysed proteomic data in P. falciparum using mass 
spectrometry revealed that peptide fragments were detected in trophozoites and 
gametocytes.  
 
Sorbitol
Synchronized
Temperature
Synchronized
Sporozoite
(ER = Early Rings | LR = Late Rings | ET = Early Trophs | LT = Late Trophs | G = Gametocytes 
ES = Early Schizonts | LS = Late Schizonts | M = Merozoites | S = Sporozoites)  
 
Figure 3.6.2: Expression levels of PfMyb2 mRNA in the intraerythrocytic life stages of P. 
falciparum 
The graph, taken from PlasmoDB version 4.5, shows PfMyb2 mRNA expression levels in the 
parasite at all stages of the intraerythrocytic lifecycle (Le Roch et al., 2003).   
 
3.6.2 Plasmodium homologues of PfMyb2 
BLASTP searches of PfMyb2 showed that the protein had homology to Myb2 
proteins found in other Plasmodium species. The alignments between PfMyb2 and 
Myb2 found in P. yoelii, P. berghei and P. vivax were performed using ClustalW2 
and can be seen in figure 3.6.3. Overall these three homologues had a 59.4%, 
58.6% and 57% identity to PfMyb2 respectively. The amino terminal ends of 
these four proteins are highly conserved and within the first 300 residues there is 
~80% similarity. This area also contains the two Myb-like DNA-binding domains, 
which are highly conserved throughout these homologues (table 3.6) and contain 
the highly conserved tryptophan and cysteine residues. 
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P.f MRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWYEWLDPSVRKTEWNKEEEEKLLHLAKLFPTQ 80 
P.y MRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWYEWLDPSVKKTEWSKEEEEKLLHLAKLFPTQ 80 
P.b MRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWYEWLDPSVKKTEWSKEEEEKLLHLAKLFPTQ 80 
P.v MRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWYEWLDPSVKKTEWSKEEEEKLLHLAKLFPTQ 80 
    *********************************************************:****.***************** 
 
P.f WRTIAPIVGRTAQQCLEHYEYLLDEAEGKVYDKNKNPRHLRPGEIDPAPESKPARADPVDMDEDEKEMLAEAKARLANTK 160 
P.y WRTIAPIVGRTAQQCLEHYEYLLDEAEGKVYDKNKNPRHLRPGEIDPAPETRPARADPVDMDDEEKEMLAEAKARLANTK 160 
P.b WRTIAPVVGRTAQQCLEHYEYLLDEAEGKVYDKNKNPRHLRPGEIDPAPETRPARADPVDMDDEEKEMLAEAKARLANTK 160 
P.v WRTIAPIVGRTAKQCLDHYEYLLDEAEGKVYDKNKNPRQLRPGEIDPAPETKPAKADPVDMDEDEKEMLAEAKARLANTK 160 
    ******:*****:***:*********************:***********::**:*******::**************** 
 
P.f GKKAKRKAREKQLEQARRLALLQKKRELKAAGITSLN--YKRKDKNKIDHSKEILFHRKPLKGFYDVKDEQNINDD-IYE 237  
P.y GKKAKRKAREKQLEQARRLALLQKKRELKAAGIVSNNH-YKKNDKNKIDHINEILFERKPLKGFYNVENEQNIEDQSQYR 239  
P.b GKKAKRKAREKQLEQARRLALLQKKRELKAAGIVSNNH-YKKNDKNKIDHINEILFERKPLKGFYNVENEQNIEDQSQYR 239  
P.v GKKAKRKAREKQLEQARRLALLQKKRELKAAGIVSTTSGYKKNDKHRIDHVKEILFERKPAKGFFDVSEEQALTHFDEKK 240  
    *********************************.* .  **::**::*** :****.*** ***::*.:** : .    . 
     
P.f NNK----------TNQKKSIKSMDVENINDAM----EYNK--NKGKRQHQ---HNNNEEANLLSTIENYDKQFNELSHLR 300 
P.y NNN--DQSISGDNNNKIRSIKSMEVENINKLT----DLGQDDNKQNKRGK---KNKNEEHDLLNAIENYDKQFNELSHLR 310 
P.b NKNNKDQSISGDSNNKIRSIKSMDVENINKLT----DLGQDDNKQNKRGK---KNKNEEHDLLNAIENYDKQFNELSHLR 312 
P.v ESK-------------YKSVKSMDVDNINEVAASPYDHHDEANASKKKTPSKGKRNNEEKDLLLAIENYDKQYNELSHLR 307 
    :.:              :*:***:*:***.      :  .  *  :::     :.:*** :** :*******:*******  
 
P.f KRVRLNLPEPILNENEIDEIIQINKEASAFNDIIKDQNDK-----LPINNILPSIESSSFILNNKDKFSNLETDFYNNNN 375 
P.y KRVRLNLPEPVLNENELDEIIQINKEATSFNQIIKDYNDNNLAN-GPINNILPSIASTPFVLNQGDMLSSIGTNFYNDNN 389 
P.b KRVRLNLPEPVLNENELDEIIQINKEATSFNQIIKDYNDNNLAN-GPINNILPSIASTPFVLNQGDMLSSIGTNFYNDNN 391 
P.v KRVRLNLPEPILNENELEEIIQINKEASSFNQIIKEQNEKNIHNGITISNILPSVTSSPFVLNERDRFSSVGTNFYS--- 384 
    **********:*****::*********::**:***: *::      .*.*****: *:.*:**: * :*.: *:**.    
 
P.f NKSIAFSSKLDLSIQQAAKNIISRKMNIPFIGMNNDYNEEEFERKNNIFQKSN--KNVPDDLEYDDTNNYHNNNNNNNNN 451 
P.y -KSIKFSSVLDHSIQQAAQSIISNNMNMPIL-----YRNEEFTKDSQKKGQNN--KSYSKNDETIEEGNIFDDDDNN--- 458 
P.b -KSIKFSSVLDHSIQQAAQSIISNNMNMPIL-----YRNEEFTKDSQKKGQYN--KSYFKNDETIEEGNIFDDDNNN--- 460 
P.v -KSIAFSSKLDFGIQQAAQSLISRNMNEPIIG-----AGGSLHTKRQVKRHINGQTNLPPRGEDAEEGPDEGPDDSGEDE 458 
     *** *** ** .*****:.:**.:** *::         .:  . :   : *  ..     *  : .   . ::..    
 
P.f TSFNSIKNSTTLYNHLDVEKNIKDVQEEIEKQKKLNEEDQQKNQKEKLTIKNKIISDIKSFKKNISLYAHSIISYKNLKN 531 
P.y -AFDDIRERS------------KKIKEEIENNKNKIKNEENIAENQRISAKNKIISDIKSFRKNISVYAQSIISYKGFKN 525 
P.b -ALDDIRERS------------KKIKEEIENNQNKIKNEENIAENQRISAKNKIISDIKSFRKNISAYAQSIISYKGFKN 527 
P.v EDLSPMLHDEPK----NIAQNVQAVKEEIESQKILNQSE--TPTKGRNHLKDKIINDIRSNQKNASLYAHSIISYKMGRN 532 
      :. : .              : ::****.::   :.:     : :   *:***.**:* :** * **:******  :* 
 
P.f DQSMMDNQTIQTTEYYD---DNYEEKIDRAKLHIKASLANLPQETNLIELQLNEEHPECDT-DNIEKDEIEKDIQDIENE 607 
P.y DNSMINPSALVNEDMIDEDDDNYEERVDRAKLLIKSSLANLPKETNVIELQIPEKDNIPND-DGEMGLELEEDAQEAEKR 604 
P.b X-SMINPSALVNENMIDEDDDNYEERVDRAKLLIKSSLANLPKETNVIELQMPEKDNIPNE-DGEIGVELEEDAQEAEKK 605 
P.v ENSVLDKNTLLS-ELYD---EDYEEKIDRAKLLIKSSLAHLPKESNVIELQIPEDLNEQESQINYEHVQVEKDMQDIEKE 608 
      *::: .:: . :  *   ::***::***** **:***:**:*:*:****: *.    :   .    ::*:* *: *:. 
 
P.f KRKNEERKEKEKFNKQNKIIRWNLPRPYFLDKINLFN---------NYMHNEYEDVHNLIQREMLLLIKNDMFNYPLRNS 678 
P.y KKMEEIKKEQDKFNKQNKVIQWNLPRPYFLQKINIFN---------VPNININEEEK-LIQKELLSLIKNDMFNYPIKGA 674 
P.b KKMEEIKKEQDKFNKQNKVIQWNLPRPCFLQKINIFN---------VPNININEEEK-LIQKELLSLIKNDMFNYPIKGA 675 
P.v KKLEQLKREQERFNSQNKVIRWNLPRPYFLPKMNLTPSVPSPPLPSTAEDATSKEVESAVLNEMLLLIKNDMFNYPMKNG 688 
    *: :: ::*:::**.***:*:****** ** *:*:                  :: .  : .*:* **********::.. 
 
P.f TPVQNKV-HVEDLENVYMNMAMKSINEEFEDMYGEASLNNNTKDDSNIDGCDEKSDNIDGCDEKSDTTNKGDDTSQCSIE 757 
P.y EPVQSMMSNSDDIEDSYIQLARNSINAEIEKNK-NLGIKNGYSFIQFVNNAVNPNTTLKENEQNENSNGTNNET---EID 750 
P.b EPVQSMTPYYDDIEDSYLQLARNSINGEIEKNK-NLGIKNGYSFIQFVNNVVNLNTTLKGNEQNGNSNGANNET---EFD 751 
P.v TPIQKRV-PLDGVEETYMRMALQSVQAELHKMTPQEGEAVNPDGEQ--ADEMKPTEEVHLSEEVHPFEEAPPSR-----T 760 
       *:*.     :.:*: *:.:* :*:: *:..   : .   . .  .   .  : .  :.::         .        
 
P.f HSSYNHIDVWEEINKNIIFCPSKNAYRFIEDVNENDKKENYKYKCEKLKNLILNDMEHYKKLENKYDIYTKGYQLKIKSY 837 
P.y EGDKN---PWADINEKVMFFPSKNVYTFVENMQEKDIIECYKYKCDNLKKLINKNMEMYKKIENKYDIYTKGYQLKLKSY 827 
P.b ETNKN---PWADINERIMFCPSKNIYTFVENMQE-DIIEYYKYKCDHLKKLINKNMEIYKKIENKYDIYTKGYQLKLKSY 827 
P.v RQPHN-FETWSELNEQVLFCPAQNAYTFIERMSERDIKESYKHTCEKLNKFIHKNMELYKKTENKYDVYTKGYERKIKGY 839 
    .   *    * ::*:.::* *::* * *:* :.* *  * **:.*::*:::* ::** *** *****:*****: *:*.* 
 
P.f KKSYDTLFNSYINCINEKEALNVLHENEKIYALTRIKEEKKENKKEIEYHKSLQKFYQDLLETNHQLKETCKQTLKVP 915 
P.y KKTFNANFNTYINHLSEQEALYNLHEGEKIYALQRMQQEKEENKKELEYHKSLQNIYAELLATNEQLKHAERNK---- 901 
P.b KKTFNANFNTYINHLSEQEALYNLHEGEQIYALQRMQQEKEENKKELEYHKSLQNIYAELLATNEQLKNAEGNK---- 901 847 
P.v KKSFDSQFSLYVNYSNEKDALSTLHEREKAYARERIREEREENQKEIEYHKSLQRLYVELLEDNKRLREGDSKPVSVS 917 859 
    **:::: *. *:*  .*::**  *** *: **  *:::*::**:**:*******.:* :**  *.:*:.   : 
 
Figure 3.6.3: Alignment of PfMyb2, P. berghei Myb2 and P. vivax Myb2 
The alignment of PfMyb2 (P.f) and Myb2 proteins found in P. yoelii (P.y), P. berghei (P.b) and P. 
vivax (P.v) was performed using ClustalW2. The R1 and R2 Myb-like DNA-binding domains of 
all four proteins have been highlighted in yellow and grey respectively. Within these domains the 
conserved tryptophan (W) and cysteine (C) residues have been highlighted in red and green 
respectively. These regions are conserved between all four Myb2 proteins.  
Identical (*), conserved (:), semi-conserved regions (.) and gaps to fit the alignment (-) are 
indicated. 
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Table 3.6: Comparison of PfMyb2 whole protein and DNA-binding domains with other 
homologues proteins. 
The table shows the percentage identity and similarity between the whole PfMyb2 protein and its 
two DNA-binding domains (R1 and R2) with four other Plasmodium homologues (PyMyb2, 
PbMyb2, PvMyb2 and PfMyb1) and a human protein (CDC5). Identity is calculated using exact 
matching base pairs while similarity takes into account both exact and conserved base pairs for the 
two proteins.  
 
Whole Protein R1 R2  
Identity  Similarity Identity  Similarity  Identity  Similarity  
PyMyb2 59.4% 73.1% 100% 100% 97.8% 100% 
PbMyb2 58.6%  72.2% 100% 100% 95.6% 100% 
PvMyb2 57% 72% 100% 100% 93.3% 100% 
PfMyb1 9.4% 17.1% 22.4% 44.9% 31.2% 50% 
CDC5 31.7% 49.1% 75% 82.7% 76.5% 84.3% 
 
3.6.3 Comparison between PfMyb2 and PfMyb1 
Alignments between PfMyb1 and PfMyb2 were performed using ClustalW2. The 
PfMyb1 protein is a Plasmodium-specific transcription factor that contains three 
carboxyl terminus Myb-like DNA-binding domains (R1, R2 and R3), which were 
the most conserved regions between the proteins (figure 3.6.4), however, there 
was still a large degree of variability. The PfMyb2 R1 and R2 domains align with 
the PfMyb1 R1 and R2 domains respectively (see table 3.6). Overall the two 
proteins had an identity and similarity of 9.4% and 17.1% respectively. PfMyb2 is 
a large protein and is more than double the size of PfMyb1, which may account 
for the low identity between the proteins. 
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PfMyb2   7 GGIWKNCEDEVLKAAVMKYGLNNWSRVASLLV-RKSAKQCKARW--YEWL     53 
PfMyb1 221 FSYTKN--DKNIEHNFLYFSETFWNEVSEKLSNNQNAKECQKMWLYYGCF     268 
    ....**  *:.::...:.:....*:.*:..|. .::**:*:..*  *... 
 
PfMyb2  54 DPSVRKTEWNKEEEEKLLHLAKLFPTQEYLLWRTIAPIV--GRTAQQCLE     101 
PfMyb1 269 EDDKQK-KWTKDEVDKLLCLSKKY---EQRNWKCIARELNTNRSPLSCFE     314 
    :...:* :*.*:*.:***.*:*.:   *...*:.**..:  .*:...*.* 
 
PfMyb2 102 HYEYLLDEAEGKVYDKNKNPRHLRPGEIDPAPESKPARADPVDMDEDEKE    151 
PfMyb1 315 QYIKI-----NKLYE-NK---------------------EKVKLERIAFN    337 
    .*..:     .*:*: **                     :.*.::..... 
 
PfMyb2 152 MLAEAKAR-LANTKGKKAKRKAREKQLEQARRLALLQKKRELKAAGITSL    200 
PfMyb1 338 VLEDIQLQILVSIIGDKNWAEVK-KHMESLNSNTSRIKKRK------TNL    380 
    :*.:.:.: *.:..*.*...:.: *.:*.........***:      *:* 
 
PfMyb2 201 NYKR                                                  204 
PfMyb1 381 NFFE                                                  384 
    *:..                                       
Figure 3.6.4: The conserved DNA-binding domains in PfMyb2 and PfMyb1 
The alignment between the DNA-binding domains of PfMyb2 and PfMyb1 was performed using 
ClustalW2. The PfMyb2 R1 and R2 domains are highlighted in yellow and grey respectively and 
align with PfMyb1 R1 (turquoise) and R2 (blue) domains. R3, the third DNA binding domain of 
PfMyb1 is highlighted in purple, but is not present in PfMyb2. The conserved tryptophan (W) and 
cysteine (C) residues, that fall within the DNA-binding domains, have been highlighted in red and 
green respectively.  
Identical (*), conserved (:), semi-conserved regions (.) and gaps to fit the alignment (-) are 
indicated.   
 
3.6.4 Homology between PfMyb2 and human CDC5 
BLASTP searches revealed that PfMyb2 had a 38% and 33% identity to the 
DNA-binding domains of c-Myb and B-Myb respectively, but it had an unusually 
high homology to the human CDC5 protein, which is the closest human 
homologue. Alignments between these two proteins using ClustalW2 revealed an 
identity and similarity of 31.7% and 49.1% respectively over the whole molecule 
(table 3.6). Like PfMyb2, CDC5 only contains two amino-terminal DNA-binding 
domains, R1 and R2, (figure 3.6.5) and there is an incredibly high similarity and 
identity (table 3.6) between these domains between the two proteins, considering 
the evolutionary distance between humans and the parasite. This contrasts with 
the low homology to PfMyb1 and other Myb proteins (table 3.6). 
 
BLASTP analysis of PfMyb2 and CDC5 revealed an additional conserved domain 
called REB1. This domain is found in Myb super-family proteins, which play a 
role in transcription as well as mRNA splicing. It was located at the amino 
terminal end of the proteins and spanned up to 289 residues in PfMyb2 and up to 
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257 residues in CDC5 (figure 3.6.5). The alignment also revealed that PfMyb2 
contains Plasmodium specific inserts, indicated by large gaps in the CDC5 
sequence (figure 3.6.5).    
 
        00000000000000000000000000000000000000000000000000000000000000000000000000000000 
PfMyb2  -MRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWYEWLDPSVRKTEWNKEEEEKLLHLAKLFPT 79 
CDC5    MPRIMIKGGVWRNTEDEILKAAVMKYGKNQWSRIASLLHRKSAKQCKARWYEWLDPSIKKTEWSREEEEKLLHLAKLMPT 80 
          ** ****:*:* ***:********* *:***:**** ******************::****.:************:** 
                    
        00000000000000000000000000000000000000000000000000000000000000000000000000000000 
PfMyb2  QWRTIAPIVGRTAQQCLEHYEYLLDEAEGKVYDK--NKNPRHLRPGEIDPAPESKPARADPVDMDEDEKEMLAEAKARLA 157 
CDC5    QWRTIAPIIGRTAAQCLEHYEFLLDKAAQRDNEEETTDDPRKLKPGEIDPNPETKPARPDPIDMDEDELEMLSEARARLA 160 
        ********:**** *******:***:*  :  ::  ..:**:*:****** **:****.**:****** ***:**:****  
 
        00000000000000000000000000000000000000000000000000000000000000000000000000000000 
PfMyb2  NTKGKKAKRKAREKQLEQARRLALLQKKRELKAAGITSLNYKRKDKNKIDHSKEILFHRKPLKGFYDVKDEQNINDDIYE 237 
CDC5    NTQGKKAKRKAREKQLEEARRLAALQKRRELRAAGIEIQ-KKRKRKRGVDYNAEIPFEKKPALGFYDTSEEN-------Y 232 
        **:**************:***** ***:***:****     *** *. :*:. ** *.:**  ****..:*:         
 
         
        000000000000000000000000000000000000000000000000000000000000 
PfMyb2  NNKTNQKKSIKSMDVENINDAMEYNKNKGKRQHQHNNNEEANLLSTIENYDKQFNELSHLRKRVRLNLPEPILNENEIDE 317 
CDC5    QALDADFRKLRQQDLDGELRSEKEGRDRKKDKQHLKRKKESDLPSAILQTSGVS---EFTKKRSKLVLPAPQISDAELQE 309 
        :    : :.::. *::.   : : .::: * ::: :.::*::* *:* : .      .. :** :* ** * :.: *::*  
 
PfMyb2  IIQINKEASAFNDIIKDQNDKLPINNILPSIESSSFILNNKDKFSNLETDFYNNNNNKSIAFSSKLDLSIQQAAKNIISR 397 
CDC5    VVKVGQAS----EIARQTAEESGITNSASSTLLSEYNVTN------------NSVALRTPRTPASQDRILQEAQNLMALT 373 
        ::::.: :    :* ::  ::  *.*  .*   *.: :.*            *.   ::   .:. *  :*:* : :    
 
PfMyb2  KMNIPFIG-MNNDYNEEEFERKNNIFQKSNKNVPDDLEYDDTNNYHNNNNNNNNNTSFNSIKNSTTLYNHLDVEKNIKDV 476 
CDC5    NVDTPLKGGLNTPLHESDFSG-----VTPQRQVVQTPNTVLSTPFRTPSNGAEGLTPRSGTT------------------ 430 
        ::: *: * :*.  :*.:*.       ..:::* :  :   :. ::. .*. :. *. .. .                   
 
PfMyb2  QEEIEKQKKLNEEDQQKNQKEKLTIKNKIISDIKSFKKNISLYAHSIISYKNLKNDQSMMDNQTIQTTEYYDDNYEEKID 556 
CDC5    -----PKPVINSTPGRTPLRDKLNIN------------------------------------PEDGMADYSDPSYVKQME 469 
              :  :*.   :.  ::**.*:                                         ::* * .* :::: 
 
PfMyb2  R-AKLHIKASLANLPQETNLIELQLNEEHPECDTDNIEKDEIEKDIQDIENEKRKNEERKEKEKFNKQNKIIRWNLPRPY 635 
CDC5    RESREHLRLGLLGLPAPKNDFEIVLPENAEKELEEREIDDTYIEDAADVDARKQAIRDAERVKEMKRMHKAVQKDLPRPS 549 
        * :: *:: .* .**  .* :*: * *:  :   :.  .*   :*  *:: .*:  .: :. ::::: :* :: :**** 
 
PfMyb2  FLDKINLFNNYMHNEYEDVHN---LIQREMLLLIKNDMFNYPLRNSTPVQNKVHVEDLENVYMNMAMKSINEEFEDMYGE 712 
CDC5    EVNETILRPLNVEPPLTDLQKSEELIKKEMITMLHYDLLHHPYEPSGNKKGKT-----------VGFGTNNSEHITYLEH 618 
         :::  *    :.    *::    **::**: ::: *::::* . *   :.*.           :.: : *.*.     . 
 
PfMyb2  ASLNNNTKDDSNIDGCDEKSDNIDGCDEKSDTTNKGDDTSQCSIEHSSYNHIDVWEEINKNIIFCPSKNAYRFIEDVNEN 792 
CDC5    NPYEKFSKE--------ELKKAQDVLVQEMEVVKQG----MSHGELSSEAYNQVWEECYSQVLYLPGQSRYTRANLASKK 686 
         . :: :*:        * ..  *   :: :..::*     .  * **  : :****  .:::: *.:. *   : ..:: 
 
PfMyb2  DKKENYKYKCEKLKNLILNDMEHYKKLENKYDIYTKGYQLKIKSYKKSYDTLFNSYINCINEKEALNVLHENEKIYALTR 872 
CDC5    DRIESLEKRLEINRGHMTTEAKRAAKMEKKMKILLGGYQSRAMGLMKQLNDLWDQIEQAHLELRTFEELKKHEDSAIPRR 766 
        *: *. : : *  :. : .: ::  *:*:* .*   *** :  .  *. : *::.  :.  * .::: *:::*.     * 
 
PfMyb2  IKEEKKENKKEIEYHKSLQKFYQDLLETNHQLKETCKQTLKVP 915  
CDC5    LECLKEDVQRQQEREKELQHRYADLLLEKETLKSKF------- 802  
        ::  *:: ::: * .*.**: * ***  :. **..         
 
 
Figure 3.6.5: Alignment of PfMyb2 and human CDC5 protein  
The alignment between PfMyb2 and CDC5 was performed using ClustalW2. The R1 and R2 
DNA-binding domains of PfMyb2 have been highlighted in yellow and grey respectively. The R1 
and R2 DNA-binding domains of CDC5 have been highlighted turquoise and pink respectively. 
The conserved tryptophan (W) and cysteine (C) residues, which fall within the DNA-binding 
domains, have been highlighted in red and green respectively. The REB1 domain has been 
highlighted by a black over-line and green underline for PfMyb2 and CDC5 respectively. 
Plasmodium specific regions are highlighted in blue.  
Identical (*), conserved (:), semi-conserved regions (.) and gaps to fit the alignment (-) indicated. 
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4. DISCUSSION 
4.1 Recombinant PfMyb2-GST protein expression in E. coli 
The pGEX-4T-2 vector was induced in E. coli to express PfMyb2, a putative P. 
falciparum transcription factor, with an amino terminal GST tag. Auto induction 
of PfMyb2-GST using Overnight Express™ Instant TB Medium resulted in 
mostly insoluble protein production, which confirms studies by various other 
groups showing that expression of recombinant P. falciparum proteins in E. coli is 
notoriously difficult. 
4.1.1 Expression of P. falciparum proteins in E. coli 
Mehlin et al. (2006) analysed the expression of 1000 P. falciparum genes in E. 
coli of which only 33.7% were able to express protein, and 6.3% of the proteins 
were soluble. Another study by Vedadi et al. (2007) also demonstrated a low 
success rate of producing soluble P. falciparum proteins in E. coli. Insolubility of 
P. falciparum proteins in a prokaryotic host is due to a number of factors 
pertaining to the physical characteristics of the protein and its gene. A high (>6) 
isoelectric point (pI) resulted in insoluble expression of proteins while a lower pI 
(<6) yielded less protein but higher solubility (Mehlin et al., 2006). The molecular 
weight of the recombinant proteins also played a role in solubility and a high 
molecular weight (>60kDa) resulted in low expression and low solubility of 
proteins (Mehlin et al., 2006, Vedadi et al., 2007). Tag technology, for example 
the addition of a GST tag, can improve solubility (http://www.emdbiosciences 
.com/html/NVG/solubility.html), but this does not seem to be the case for P. 
falciparum proteins (Mehlin et al., 2006). The current study also demonstrated 
that PfMyb2-GST was insoluble despite the presence of a GST tag. The PfMyb2-
GST fusion protein has a pI >6 and a molecular weight of 134kDa and therefore 
its insolubility corroborates the Mehlin et al (2006) study.  
 
The lack of homology of the target proteins to E. coli proteins impacted 
negatively on protein expression (Mehlin et al., 2006). Myb proteins have been 
identified in slime moulds and fungi (Lipsick, 1996), however, these proteins do 
not seem to be present in bacteria. During the BLASTP searches on PfMyb2, no 
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homology to any possible endogenous E. coli Myb was found and this could have 
contributed to the insolubility of the recombinant protein. 
4.1.2 Strategies to improve expression of soluble PfMyb2-GST 
The high AT content of the parasite genome results in the prevalence of certain 
codons that are not utilised frequently in E. coli and large stretches of adenosines 
and thymidines may also cause problems in expression of P. falciparum genes in 
bacteria. Two codons, ATA and AGA expressing tRNAs for isoleucine and 
arginine respectively, are common in P. falciparum and are particularly rare in E. 
coli (Mehlin et al., 2006). To correct this potential problem, Rosetta E. coli cells 
containing the pRARE plasmid were used in this study. This plasmid expresses 
tRNAs for arginine, isoleucine, glycine, leucine and proline and therefore 
facilitates the production of P. falciparum proteins.  
 
The pGEX-4T-2 vector contains a lac promoter, which in the presence of lactose 
induces expression of the inserted gene fragment. Induction of PfMyb2-GST was 
initially tested using IPTG. This molecule activates beta-galactosidase, which 
binds the lac repressor and induces the use of lactose resulting in expression of 
genes under control of the lac promoter. A number of varying induction 
conditions were tested including IPTG concentration, temperature and the length 
of time of induction. Altering these variables independently and together did not 
improve the expression or solubility of PfMyb2-GST. Therefore Overnight 
Express™ Instant TB Medium was utilised. This medium does not require the 
addition of IPTG and allows the bacterial cells to grow to a high density initially, 
followed by autoinduction of protein expression due to a build up of lactose. It 
resulted in improved recombinant protein expression although ~90% of the 
protein was insoluble. The amount of soluble protein was too small to purify using 
affinity chromatography and it was therefore decided to isolate the insoluble 
protein from the bacterial inclusion bodies.   
4.1.3 Purification of PfMyb2-GST from inclusion bodies 
When the protein induction rate is very high and large quantities of recombinant 
protein is produced, the protein is not folded correctly and is packaged into 
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inclusion bodies within the bacterial cell (Vallejo and Rinas, 2004). Although the 
recombinant protein does not have the correct conformation it can be isolated 
from the inclusion bodies, solubilised with a strong denaturant (such as guanidine 
hydrochloride) and then refolded into its presumed native shape by slowly 
decreasing the concentration of the denaturant. Inclusion bodies in the cell are a 
different size to the rest of the cellular components and can easily be isolated 
based on their density and size. They contain very few cellular components other 
than the insoluble recombinant protein, which results in a high yield of pure 
protein. The inclusion bodies also protect the protein from degradation and 
cellular proteases (Singh and Panda, 2005).  
 
The refolding method and affinity purification of the refolded PfMyb2-GST had 
to be optimised. Although some of the PfMyb2-GST did not bind to the 
glutathione particles, that which did remained tightly bound even after elution 
with a buffer containing 50mM glutathione. This indicated that the dissociation of 
bound PfMyb2-GST was not efficient and the amount of glutathione in the buffer 
was increased to a final concentration of 200mM, four times that of the 
recommended concentration.  
 
Minor protein bands at lower molecular weights than that expected for PfMyb2-
GST were detected in Western blots. These were presumably truncated forms of 
PfMyb2-GST, as the GST tag is attached to the amino terminal end of the protein 
and would therefore also be attached to any truncated recombinant protein. The 
PfMyb2-GST construct is very large (3.5kb) and this would increase the 
likelihood of premature termination of translation. The majority of the 
recombinant protein purified from the inclusion bodies represented the desired full 
length PfMyb2-GST. The yield was however, still relatively low (~20-40ug per 
500ml culture of E. coli). Larger amounts of recombinant protein could be 
obtained if the volume of the culture is increased, even though the expression is 
poor. It was not known if the protein had refolded into its native state but the fact 
that it did not precipitate during refolding implied that it was in its correct 
conformation. The verification of correct conformation of the refolded protein 
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could be done using circular dichroism (CD). This measures the difference in a 
molecule’s absorption of left- and right-handed polarised light. Secondary 
structures of proteins including helices, coils and -sheets all exhibit different CD 
spectra (Johnson, 1990). Therefore, the secondary structure of a protein can be 
determined by comparing its CD spectrum to that of helices, coils and -sheets. In 
this case the reference curve obtained for the soluble recombinant protein can be 
compared to that obtained for the refolded protein, however, CD requires 
relatively large amounts of soluble protein to obtain the reference curve and there 
may not be enough soluble PfMyb2 available. Another method to determine 
correct refolding of the insoluble recombinant protein would be to test its ability 
to perform its function of DNA binding, using DNA-binding studies.   
4.1.4 Additional strategies to enhance soluble expression of PfMyb2 
There are a number of other options that may be tested in the future to try and 
enhance the soluble expression of PfMyb2.  
 
Instead of producing the PfMyb2 gene through PCR amplification of genomic P. 
falciparum DNA, a gene consisting of codons optimised for E. coli can be 
synthesized (Burgess-Brown et al., 2008). This will eliminate the codon bias 
present in P. falciparum genes due to their high AT content. However, Mehlin et 
al. (2006) did not find any differences in soluble expression using this technique 
although other studies have shown its efficacy (Zhou et al., 2004, Yadava and 
C.F., 2003). PfMyb2 is a large gene (2.7kb) and codon optimisation may not be 
cost effective especially since there is no guarantee of success.  
 
Molecular chaperones facilitate the correct folding of proteins in the cell (Cole, 
1996) and this can be used to increase soluble protein expression by transforming 
E. coli cells that contain the pGEX-PfMyb2 constructs with a plasmid that 
expresses chaperones. Another modification that may result in more soluble 
protein is the use of a different soluble tag such as N utilization substance A 
(NusA), maltose-binding protein (MBP) (Nallamsetty and Waugh, 2006), 
thioredoxin (TRX), Z-domain from protein A (ZZ) and Gb1-domain from protein 
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G (Gb1) (Hammarstrom et al., 2002). These amino-linked fusion tags, have 
different effects on recombinant protein expression and solubility in E. coli 
(Hammarstrom et al., 2002, Braun et al., 2002, Chelur, 2008) and thus the most 
suitable tag for a protein has to be assessed on an individual basis. Chelur (2008) 
also report that fusion tags may hinder protein expression and solubility as well as 
alter its conformation which can cause a loss of the proteins function. In the 
current study, fusion of an amino-terminal GST to PfMyb2 produced very little 
soluble protein. 
  
Finally, the baculovirus expression system could be utilised for the expression of 
PfMyb2. In this system, vector DNA containing the gene of interest is inserted 
into baculoviral DNA through recombination and transfected into insect cells 
where the gene is induced to express recombinant protein (Ausubel et al., 1995). 
The advantage of this system is that insect cells are eukaryotic and this may 
facilitate correct folding of PfMyb2. Mehlin et al. (2006) had good success with 
this system. Out of 17 proteins that were insoluble in E. coli, they were able to 
produce seven soluble proteins using the baculovirus expression system. The 
pTriEx-3 vector was available in Prof Coetzer’s laboratory and can be used to 
express protein in bacteria, mammalian, as well as insect cells utilising the 
baculovirus system.  The PfMyb2 insert was cut out of the pGEX-PfMyb2 vector 
constructs and inserted into pTriEx-3. However, the insert is not in frame and new 
primers will have to be designed to clone PfMyb2 into this and other vectors. 
Other pTriEx vectors that are available contain a signal for export, which secretes 
the recombinant protein from the insect cell into the culture supernatant allowing 
for easy retrieval of the protein (Novagen insect cell expression catalogue).   
 
4.2 Possible cellular functions of PfMyb2  
4.2.1 Role of PfMyb2 as a transcription factor 
Expression studies (Le Roch et al., 2003, Bozdech et al., 2003) and mass 
spectrometry analysis (Florens et al., 2004, Florens et al., 2002) indicated that 
PfMyb2 is expressed at low levels throughout the intraerythrocytic lifecycle of the 
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parasite, while peptide fragments have been detected in gametocytes and 
trophozoites. Sequence alignments of the Myb-like DNA binding regions between 
PfMyb2, Myb2 in other Plasmodium species, as well as with PfMyb1 showed that 
these domains contain the characteristic Myb HTH motif with regularly spaced 
tryptophan residues and a highly conserved cysteine residue. These conserved 
residues play a role in stabilising the DNA-binding interaction. EMSA studies 
performed on the DNA-binding domains of PfMyb2 showed that they bound to a 
consensus MRE, a MRE from the mim1 gene in chicken and two putative MREs 
in the promoters of two P. falciparum genes: pfmap1 and pfcrk1 (Meyersfeld, 
2005). The pfcrk1 gene is expressed mainly in gametocytes and encodes a kinase 
that is important in sexual differentiation of the parasite (Doerig et al., 1995), 
while the pfmap1 gene encodes a kinase that plays a role in cell cycle control 
(Doerig et al., 1996). This supports the fact that PfMyb2 may activate genes 
involved in cell cycle control and that its function overlaps with PfMyb1, a P. 
falciparum-specific transcription factor that regulates genes involved in cell cycle 
and differentiation (Boschet et al., 2004). Immunofluorescence localisation assays 
with an antibody specific for PfMyb2 showed that the protein is present in the 
parasite nucleus (Meyersfeld et al., 2008), which further corroborates its role as a 
transcription factor.    
 
4.2.1.1 Possible interactive role of PfMyb2 and PfMyb1 
A combinatorial effect of transcription factor binding has been suggested by Van 
Noort and Huynen (2006). They speculate that transcription factors can bind in 
different combinations to different regulatory cis-sequences, which may account 
for the apparent scarcity of transcription factors in the P. falciparum genome. The 
combinatorial effect may be a mechanism employed by PfMyb2 as it binds to the 
same MREs as PfMyb1. PfMyb2 contains only two Myb-like DNA-binding 
domains (R1 and R2), while in most cases the Myb family proteins contain three 
of these domains (R1, R2 and R3, see figure 4.2). Studies in c-Myb have shown 
that R2 and R3 interact directly with the DNA while the R1 motif is not essential 
for DNA-binding (Howe et al., 1990). Therefore the loss of R3 in PfMyb2 
suggests that DNA binding could occur by a different mechanism to that of 
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PfMyb1, which has all three binding motifs. Due to the difference in their DNA-
binding domains, these proteins may also display variable affinity for the MREs, 
further implementing the combinatorial effect.  
 
PfMyb2 mRNA is expressed throughout the intraerythrocytic lifecycle and 
PfMyb1 mRNA is also present in all stages except late schizonts. Both have 
differential levels of mRNA expression (measured in Affymetrix MOID 
expression values) with PfMyb2 peaking in the early ring stage at 200 and 
PfMyb1 in the early trophzoite stage at 70 (Le Roch et al., 2003). This may 
suggest that PfMyb2 transcriptionally activates more genes than PfMyb1 or that it 
has other roles in the parasite (discussed in sections 4.2.2 and 4.2.3). 
 
 
Figure 4.2 The general structure of PfMyb2, PfMyb1 and human CDC5 proteins 
The diagram depicts the general structure of PfMyb2 and two homologues proteins, PfMyb1 and 
human CDC5. The DNA-binding domains (R1-R3) are indicated in red. PfMyb2 and CDC5 only 
have the R1 and R2 motifs at the amino terminal end, while PfMyb1 contains all three motifs at 
the carboxyl end of the protein. PfMyb2 and CDC5 also have an amino terminal REB1 domain, 
indicated in green, that is not present in PfMyb1. A transactivation domain, indicated in yellow, is 
present in CDC5 only. The number of amino acids in each protein is indicated in each diagram. 
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4.2.1.2 Role of PfMyb2 based on its homology to human CDC5 
The human CDC5 protein and PfMyb2 contain a ~50% similarity to one another 
and have a marked conservation in their amino terminal ends. The overall 
homology between these two proteins is much greater than that of PfMyb2 and 
PfMyb1, where conserved residues are only apparent in the DNA-binding regions. 
The amino terminal ends of these two proteins contain the R1 and R2 DNA-
binding domains, which have up to ~85% similarity, as well as the REB1 domain, 
which incorporates R1 and R2 (figure 4.2). Based on this homology PfMyb2 may 
have functions more similar to CDC5 rather than to PfMyb1.  
 
The CDC5 protein is highly conserved both structurally and functionally amongst 
eukaryotes and appears to be a multifunctional protein (Lei et al., 2000). Many 
studies have investigated yeast and human CDC5 to ascertain their functions in 
the cell. CDC5 positively regulates the cell cycle G2/M progression, which 
involves the mitotic division of the cell after DNA replication has taken place 
(Bernstein and Coughlin, 1998). In addition to the two amino terminal Myb-like 
tandem repeat motifs, CDC5 also contains a central transcriptional activation 
domain but this is not present in PfMyb2.  CDC5 is able to bind a double stranded 
DNA motif (GATTTANCATAA, where N can be any base), which has a core 
HTH binding motif (ANCA) (Bernstein and Coughlin, 1998, Bernstein and 
Coughlin, 1997, Lei et al., 2000). These factors and the similarity of CDC5 to 
Myb family proteins, which function as transcriptional regulators, imply that it 
regulates the cell cycle by transcriptional activation. The high sequence similarity 
between PfMyb2 and CDC5, as well as the fact that PfMyb2 bound to MREs, 
supports the notion that PfMyb2 is a transcription factor, which may control 
expression of genes in the cell cycle as does CDC5 and PfMyb1.  
4.2.2 Possible role of PfMyb2 in RNA processing 
CDC5 has additional functions in the cell that the Myb family proteins are not 
involved in. This may explain the differences noted between CDC5 and c-Myb 
mRNA expression levels. In humans, CDC5 has a greater level of expression 
compared to c-Myb (Bernstein and Coughlin, 1997) and this pattern is similar in 
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P. falciparum, where more PfMyb2 mRNA is present when compared to PfMyb1 
(Le Roch et al., 2003). One other function of CDC5 is its involvement in mRNA 
processing. It forms part of the spliceosome (Ajuh et al., 2001), a protein complex 
that processes pre-mRNA into mature mRNA by splicing out introns and joining 
exons together. CDC5 is required for the first biochemical step in processing pre-
mRNA and if its levels are disrupted it results in an accumulation of pre-mRNA 
and defective mRNA splicing (Ajuh et al., 2001, Burns et al., 1999). Therefore the 
involvement of CDC5 in the cell appears to be multifunctional and it plays a role 
in regulating the cell cycle by controlling gene expression through transcriptional 
as well as post-transcriptional mechanisms. It would be interesting to ascertain if 
PfMyb2, like CDC5, plays a role in pre-mRNA splicing by forming part of the 
spliceosome in the malaria parasite.  
4.2.3 Possible role of PfMyb2 in chromatin remodelling 
The RNA polymerase I enhancer binding (REB1) domain may also provide clues 
to additional functions of PfMyb2. This domain is common to both PfMyb2 and 
CDC5 and was identified as a conserved domain during BLASTP searches of 
these two proteins. REB1 is a multifunctional protein associated with Myb family 
proteins and it has been studied mainly in yeasts. It is one of the general 
regulatory proteins that function in transcription (Ju et al., 1990) by binding to 
DNA consensus motifs (CCGGGTA and CGGGTRRPuPu) and enhancing the 
binding of other specific transcription factors. REB1 appears to play a role in 
transcriptional termination by causing pol I (responsible for the expression of 
ribosomal RNA genes (Fox et al., 1993)) or pol II, to pause along the DNA strand 
(Lang and Reeder, 1993, Lang et al., 1994, Paule and White, 2000). In addition to 
these functions REB1 is also involved in chromatin remodelling (Angermayr and 
Bandlow, 1997). REB1 binds to DNA and partitions it into active euchromatin by 
altering the shape of the chromosome or inhibiting nucleosome binding to 
flanking regions at the REB1 binding site, producing a nucleosome free region. 
This may stop the spread of silent chromatin encroaching on active chromatin 
(Fourel et al., 2002, Raisner et al., 2005, Yu et al., 2003). In yeast the REB1 
protein is one of the factors that controls the expression of a cyclin needed for 
  
Discussion                                                                                                              79 
G2/M transition (Van Slyke and Grayhack, 2003), which is the same point in the 
cell cycle that CDC5 regulates. It would be interesting to evaluate the P. 
falciparum genome for REB1 DNA-binding motifs and perform DNA-binding 
studies with recombinant PfMyb2, if any such sequences are identified. If PfMyb2 
were to bind to these regions, additional studies to assess whether it controls gene 
expression in a transcriptional or an epigenetic manner would provide valuable 
insight into the role of this protein in the parasite. 
 
4.3 Future studies 
Bioinformatic analysis of PfMyb2 has revealed conserved motifs, which provide 
clues to the possible functions of this protein. However, until these are validated 
using molecular techniques they still remain as speculations. This study has 
produced a vector construct containing the full length PfMyb2 gene that can be 
used to express recombinant PfMyb2 protein to validate these putative functions. 
Since the soluble expression of this protein is very low, use of the baculovirus 
system in insect cells may enhance the production of soluble recombinant protein 
to be utilised in these studies. 
 
The DNA binding regions of recombinant PfMyb2 have been used in our 
laboratory for EMSA studies which showed that these domains bound MREs from 
two P. falciparum genes (Meyersfeld, 2005). The protein has also been localised 
to the nucleus (Meyersfeld et al., 2008) and all this evidence is strong support that 
PfMyb2 is a transcription factor. The full length recombinant PfMyb2 protein can 
be used in DNA-binding studies to MREs to further validate these data. EMSAs 
could also be utilised to determine if PfMyb2 is able to bind to REB1 consensus 
repeats, indicating the protein’s ability to regulate gene expression through 
possible epigenetic means. Reporter gene assays would be required to verify that 
PfMyb2 is able to trans-activate and drive expression of a downstream reporter 
gene, such as luciferase. Studies using gene knockdown and knockout 
technologies would also provide insight into the role of PfMyb2 in the parasite. 
 
  
Discussion                                                                                                              80 
Based on the high homology to CDC5 it would be interesting to see if PfMyb2 
also forms part of the parasite’s spliceosome. PfMyb2 may play a role in pre-
mRNA splicing by forming part of this complex or by directly interacting with 
pre-mRNA molecules. Direct protein-RNA interactions in P. falciparum have 
been demonstrated by Gunasekera et al. (2007). Similar experiments to 
demonstrate the interaction of PfMyb2 with RNA will highlight its possible role 
in post-transcriptional control of gene expression.  
 
4.4 Conclusion 
This study has resulted in the production of the full length, putative transcription 
factor, PfMyb2 as a recombinant GST fusion protein. Future studies to elucidate 
the function of this protein in P. falciparum will provide valuable insight into 
mechanisms of gene regulation, which are currently not well understood. By 
studying the parasite’s biology we will slowly gain understanding of the complex 
lifecycle of this organism and find novel means of intervention to help control the 
parasite and the burden of malaria. 
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5. LIST OF SUPPLIERS 
 
Acrylamide Promega, USA 
AB plasma South African National Blood 
Transfusion Service 
ACD tubes Beckton Dickinson, UK 
Agar Merck, Germany 
Agarose Hispanagar, Spain 
Ammonium chloride Sigma, USA 
Ammonium persulphate Promega, USA 
Ampicillin Roche, Germany 
  
-mercaptoethanol Merck, USA 
Bactotryptone Beckton Dickinson, UK 
BamH1 restriction enzyme Fermentas, RSA 
Beckman J2-21 centrifuge and JA-17 rotor Beckman, USA 
Bis-acrylamide Promega, USA 
Blue loading dye Fermentas, RSA 
Bovine serum albumin Roche, Germany 
Bromophenol blue BDH, UK 
BRL model S2 electrophoresis apparatus Amersham, UK 
BugBuster®  Novgen, USA 
  
Centrifuge tubes Nunc, Denmark 
Chloramphenicol Sigma, USA 
Chloroform Associated Chemical 
Enterprises  
Coomassie brilliant blue R-250 Merck, Germany 
Cryotubes Nunc, Denmark 
Culture flasks Nunc, Denmark 
  
DC power supply, PS 500X Hoefer, USA 
DH5 competent cells Invitrogen, USA 
Dialysis tubing Sigma, USA 
DNA MassRuler™ Fermentas, RSA 
DTT Behringer Mannheim GmbH 
  
EDTA BDH, RSA 
Eppendorf 5415R centrifuge Merk, USA 
Eppendorf TripleMaster PCR system Merk, USA 
Ethanol Saarchem, RSA 
Ethidium bromide Sigma, USA 
  
Filter paper (extra thick) Biorad, USA 
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Gentamicin Roche, Germany 
GenElut™ plasmid miniprep kit Sigma, USA 
Glucose Saarchem, RSA 
Glutathione Sigma, USA 
Glycerol Saarchem, RSA 
Glycine BDH, RSA 
Gyanidine-hydrochloride Calbiochem, Germany 
  
Hepes buffer Invitrogen, USA 
HyBond™-C Extra nitrocellulose membrane Amersham, UK 
Hypoxanthine solution Sigma, USA 
  
IPTG Invitrogen, USA 
Isopropanol Saarchem, RSA 
  
Kanamycin Roche, Germany 
  
Laminar flow hood Labotec, RSA 
L-Lysozyme Mecrk, USA 
  
Methanol Saarchem, RSA 
Mighty Small duel casting tray Hoefer, USA 
MiniElute Gel Extraction Kit Qiagen 
Mouse anti-his antibody Amersham, UK 
  
Oligonucleotide primers Inquaba biotech, RSA 
Overnight Express™ Instant TB Medium EasyPak Novagen, USA 
  
PageRuler™ prestained protein ladder Fermentas, RSA 
Para film Whatman, UK 
PCR Triple master mix kit Roche, Germany 
PCR Master mix Eppendorf, Germany 
PCR tubes QSP, USA 
Peristaltic pump SJ-1211 SIS, USA 
pET-41a Novagen, USA 
PGEX-4T-2 expression vector Novagen, USA 
pTriEx-3 Novagen, USA 
Phenol Sigma, USA 
Ponceau S Sigma, USA 
Potassium acetate Saarchem, RSA 
Potassium chloride Saarchem, RSA 
Potassium di-hydrogen orthophosphate Saarchem, RSA 
Proteinase-K Roche, Germany 
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Protease inhibitor cocktail set III Calibiochem, USA 
  
Rapid DNA ligation kit Roche, Germany 
Rapid Haematomolgy staining kit SAIMR, RSA 
Ribonuclease A Fermentas, RSA 
PMFS Roche, Germany 
RPMI culture medium Invitrogen, USA 
Rosetta 2(DE3) competent cells Novagen, USA 
  
Saponin USB, UK 
SDS BDH, UK 
Sorbitol Sigma, USA 
Sodium acetate Saarchem, RSA 
Sodium bicarbonate Saarchem, RSA 
Sodium chloride Saarchem, RSA 
Sodium citrate Saarchem, RSA 
Sodium di-hydrogen orthophosphate Saarchem, RSA 
Sodium hydroxide Saarchem, RSA 
Spectrophotometer (SU65) Beckman, USA 
Syngene gel doc system Synoptics, UK 
  
Tango™ buffer Fermentas, RSA 
TEMED Promega, USA 
Tris BDH, UK 
Triton X-100 Sigma, USA 
Tween® 20 detergent Calibiochem, USA 
  
Yeast extract Oxoid, UK 
  
Xho1 restriction enzyme Fermentas, RSA 
  
Zeiss Axiostar microscope Zeiss, Germany 
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6. APPENDIX  
A-1: pET-41a 
The expression vector adds eight codons for histidine to the 3’ end of the inserted 
gene which results in a carboxyl terminal his tag in the recombinant protein.  
Vector map drawn with PlasMapper 2.0 
(http://wishart.biology.ualberta.ca/PlasMapper/) 
The cloning/expression region was taken from the pET-41a vector map on the 
Novagen website 
(http://www.merckbiosciences.com/g.asp?f=NVG/pETtable.html#pet41a). 
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A-2: pGEX-4T-2 
The pGEX-4T-2 vector with PfMyb2 gene inserted into the BamHI and XhoI sites of 
the MCS. The expression vector adds a 5’ GST sequence to the inserted gene which 
results in an amino terminus GST tag in the recombinant protein.  
Vector map drawn with PlasMapper 2.0 
(http://wishart.biology.ualberta.ca/PlasMapper/) 
The cloning/expressing region was taken from the vector map available on the GE-
healthcare life sciences website (www1.gelifesciences.com). 
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A-3: PfMyb2-GST gene sequence in pGEX-4T-2 
GST start Codon: ATG; Stop codon: TGA 
GST gene: Black; PfMyb2 gene insert: Green; vector sequence: Purple 
Restriction enzyme sites: BamHI: GGATCC   
                                         XhoI: CTCGAG  
pGEX Sequencing primers:  
 5' primer, nucleotides 869-891: 5'GGGCTGGCAAGCCACGTTTGGTG3' 
 3' primer, nucleotides 1042-1020: 5'CCGGGAGCTGCATGTGTCAGAGG 3' 
PfMyb2 sequencing forward primers: 
PfMyb2WholeSeq1F: 5'ACTTGCAAATACGAAAGG3' 
PfMyb2WholeSeq2F: 5'GATCTAAGTATACAACAAGCAG3' 
            PfMyb2WholeSeq3F: 5'CCAGAATGTGATACGGAC3' 
 
 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGA
AGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATT
ATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGTTGTCCA
AAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTT
TGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAA
ATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCG
TTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATG
GCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGAGGATTC
AAATAAAAGGAGGTATATGGAAAAATTGTGAGGATGAAGTTCTTAAAGCAGCTGTTATGAAATATGGTTTAAATAATTGGTCAAGG
GTCGCATCTTTATTAGTTCGTAAATCAGCTAAACAGTGTAAGGCGAGGTGGTATGAATGGCTTGATCCATCAGTTAGAAAAACCGA
ATGGAATAAAGAAGAAGAAGAAAAACTTTTACATCTAGCCAAATTGTTTCCAACACAATGGAGAACCATAGCACCTATAGTAGGAA
GAACAGCACAACAATGTTTAGAACATTATGAATATCTACTTGATGAAGCGGAAGGAAAGGTTTATGATAAAAATAAGAACCCACGA
CATCTAAGGCCAGGTGAAATAGACCCTGCTCCTGAATCCAAACCAGCACGTGCAGATCCTGTAGATATGGATGAAGATGAAAAAGA
AATGCTTGCAGAAGCTAAGGCAAGACTTGCAAATACGAAAGGTAAAAAAGCAAAAAGAAAAGCTAGAGAAAAACAACTGGAACAAG
CTAGGAGATTAGCTTTATTACAAAAAAAGAGAGAATTAAAAGCAGCAGGGATAACATCATTAAATTATAAAAGAAAAGATAAAAAT
AAAATTGATCATTCGAAAGAAATATTATTTCATAGGAAACCATTAAAAGGTTTTTATGATGTTAAAGATGAACAAAATATTAATGA
TGATATATATGAAAATAATAAGACAAATCAGAAGAAAAGTATAAAATCAATGGATGTTGAAAATATTAATGATGCTATGGAATATA
ATAAAAATAAAGGTAAACGACAACATCAACATAATAATAATGAAGAAGCAAATTTGTTATCTACCATAGAAAATTATGATAAACAA
TTTAACGAATTAAGTCATTTAAGAAAAAGGGTTCGATTGAATTTACCAGAACCTATATTAAATGAAAATGAAATAGATGAAATAAT
ACAAATAAATAAAGAAGCATCAGCATTTAACGATATTATAAAAGATCAAAACGATAAATTACCAATAAATAATATTTTACCAAGTA
TTGAAAGCTCCTCATTTATATTAAACAATAAAGATAAATTTTCAAACTTGGAAACAGATTTTTATAATAATAATAATAATAAATCA
ATTGCTTTTTCTAGTAAACTAGATCTAAGTATACAACAAGCAGCAAAAAATATCATTTCTCGAAAAATGAATATTCCATTTATAGG
AATGAACAATGATTATAATGAAGAAGAATTCGAAAGAAAAAATAATATATTTCAAAAGAGTAATAAGAATGTTCCTGATGATTTAG
AATATGATGACACGAACAATTATCATAATAATAATAATAATAATAATAATAATACTTCTTTTAATTCGATCAAAAATTCCACAACC
CTTTATAATCATTTGGATGTAGAAAAAAATATAAAAGACGTACAAGAAGAAATTGAAAAACAAAAGAAATTAAATGAAGAAGATCA
ACAAAAGAATCAAAAAGAAAAGTTAACTATTAAAAATAAAATTATTAGTGATATTAAAAGTTTTAAAAAAAATATTAGTTTATATG
CTCATTCTATTATTTCTTATAAAAATTTAAAAAATGATCAATCTATGATGGATAATCAAACTATACAAACAACTGAATATTATGAT
GATAATTATGAAGAGAAAATCGATCGAGCAAAATTACATATTAAAGCATCGTTAGCCAATTTACCCCAAGAAACGAATCTTATAGA
ACTTCAATTAAATGAAGAACATCCAGAATGTGATACGGACAATATAGAAAAAGATGAAATAGAAAAAGATATACAAGATATTGAAA
ATGAAAAAAGAAAAAACGAAGAAAGAAAAGAAAAAGAAAAATTTAATAAGCAAAATAAAATTATTAGATGGAATTTACCTAGACCA
TATTTCTTAGATAAAATTAATCTCTTTAATAATTATATGCACAATGAATATGAAGATGTCCATAATTTAATACAAAGAGAGATGCT
CCTCTTAATAAAAAATGATATGTTTAATTATCCCCTCAGAAATTCAACACCAGTACAAAATAAAGTTCATGTGGAAGATCTCGAAA
ACGTATACATGAATATGGCTATGAAGAGTATAAATGAGGAGTTCGAAGATATGTATGGCGAAGCATCATTAAATAACAACACAAAG
GATGATTCTAATATTGATGGGTGTGATGAAAAGAGTGATAATATTGATGGTTGTGATGAAAAAAGTGATACAACTAATAAAGGTGA
TGATACGTCCCAATGTAGTATCGAGCATAGTTCATATAATCATATCGATGTGTGGGAAGAAATTAACAAAAATATAATTTTTTGCC
CATCAAAAAATGCATATCGCTTTATTGAAGATGTTAATGAAAACGATAAAAAAGAAAATTACAAATACAAATGTGAAAAATTAAAA
AATTTAATTTTAAATGATATGGAACATTATAAAAAATTAGAAAATAAATATGATATTTATACAAAAGGATATCAACTAAAAATTAA
AAGTTATAAAAAATCATATGATACTCTATTTAATTCATATATTAATTGTATTAACGAAAAAGAAGCTTTAAATGTTCTACATGAAA
ATGAAAAAATATATGCATTAACAAGAATTAAAGAAGAAAAAAAGGAAAATAAAAAAGAAATCGAATATCATAAATCATTACAAAAG
TTTTATCAAGACCTTTTAGAAACAAATCATCAATTAAAAGAAACATGTAAACAAACGTTAAAGGTGCCACTCGAGCGGCCGCATCG
TGACTGACTGACGATCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGG 
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A-4: PfMyb2-GST fusion protein sequence 
Molecular weight: 134 kDa (PfMyb2: 108 kDa; GST: 26kDa) 
Number of residues: 1148 residues 
pI: 6.59  
Extinction coefficient: 146460M-1 cm-1 
GST Start Codon: M; Stop codon: - 
GST sequence: Black 
PfMyb2 sequence: Green  
Vector sequence: Purple 
Restriction enzyme sites: BamHI: GS 
             XhoI: LE 
 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLC
HKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQ
ATFGGGDHPPKSDLVPRGSMRIQIKGGIWKNCEDEVLKAAVMKYGLNNWSRVASLLVRKSAKQCKARWY
EWLDPSVRKTEWNKEEEEKLLHLAKLFPTQWRTIAPIVGRTAQQCLEHYEYLLDEAEGKVYDKNKNPRH
LRPGEIDPAPESKPARADPVDMDEDEKEMLAEAKARLANTKGKKAKRKAREKQLEQARRLALLQKKREL
KAAGITSLNYKRKDKNKIDHSKEILFHRKPLKGFYDVKDEQNINDDIYENNKTNQKKSIKSMDVENIND
AMEYNKNKGKRQHQHNNNEEANLLSTIENYDKQFNELSHLRKRVRLNLPEPILNENEIDEIIQINKEAS
AFNDIIKDQNDKLPINNILPSIESSSFILNNKDKFSNLETDFYNNNNNKSIAFSSKLDLSIQQAAKNII
SRKMNIPFIGMNNDYNEEEFERKNNIFQKSNKNVPDDLEYDDTNNYHNNNNNNNNNTSFNSIKNSTTLY
NHLDVEKNIKDVQEEIEKQKKLNEEDQQKNQKEKLTIKNKIISDIKSFKKNISLYAHSIISYKNLKNDQ
SMMDNQTIQTTEYYDDNYEEKIDRAKLHIKASLANLPQETNLIELQLNEEHPECDTDNIEKDEIEKDIQ
DIENEKRKNEERKEKEKFNKQNKIIRWNLPRPYFLDKINLFNNYMHNEYEDVHNLIQREMLLLIKNDMF
NYPLRNSTPVQNKVHVEDLENVYMNMAMKSINEEFEDMYGEASLNNNTKDDSNIDGCDEKSDNIDGCDE
KSDTTNKGDDTSQCSIEHSSYNHIDVWEEINKNIIFCPSKNAYRFIEDVNENDKKENYKYKCEKLKNLI
LNDMEHYKKLENKYDIYTKGYQLKIKSYKKSYDTLFNSYINCINEKEALNVLHENEKIYALTRIKEEKK
ENKKEIEYHKSLQKFYQDLLETNHQLKETCKQTLKVPLERPHRD- 
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A-5: pTriEx-3 
The pTriEx-3 vector with PfMyb2 gene inserted into the BamHI and XhoI sites of the 
MCS.  
The expression vector adds eight codons for histidine to the 3’ end of the inserted 
gene which results in a carboxyl terminal his tag in the recombinant protein. 
Vector map drawn with PlasMapper 2.0 
(http://wishart.biology.ualberta.ca/PlasMapper/) 
The cloning/expression region was taken from form the pTriEx3 vector map on the 
Novagen website 
(http://www.merckbiosciences.com/html/NVG/pTriExTable.html).  
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A-6: PfMyb2-his gene sequence in pTriEx-3 
 
Vector start codon: ATG; PfMyb2 start codon: ATG;  
Stop codon: TAA; Premature stop codon: TGA 
PfMyb2 gene insert: Green; Vector sequence: Black; his tag: H 
Restriction enzyme sites: BamHI: GGATCC   
                                             XhoI: CTCGAG 
 
ATGGCGATATCCCGGGAGCTCGTGGATCCATGAGGATTCAAATAAAAGGAGGTATATGGAAAAATTGTGAGGATGAAGTTCTTAAA
GCAGCTGTTATGAAATATGGTTTAAATAATTGGTCAAGGGTCGCATCTTTATTAGTTCGTAAATCAGCTAAACAGTGTAAGGCGAG
GTGGTATGAATGGCTTGATCCATCAGTTAGAAAAACCGAATGGAATAAAGAAGAAGAAGAAAAACTTTTACATCTAGCCAAATTGT
TTCCAACACAATGGAGAACCATAGCACCTATAGTAGGAAGAACAGCACAACAATGTTTAGAACATTATGAATATCTACTTGATGAA
GCGGAAGGAAAGGTTTATGATAAAAATAAGAACCCACGACATCTAAGGCCAGGTGAAATAGACCCTGCTCCTGAATCCAAACCAGC
ACGTGCAGATCCTGTAGATATGGATGAAGATGAAAAAGAAATGCTTGCAGAAGCTAAGGCAAGACTTGCAAATACGAAAGGTAAAA
AAGCAAAAAGAAAAGCTAGAGAAAAACAACTGGAACAAGCTAGGAGATTAGCTTTATTACAAAAAAAGAGAGAATTAAAAGCAGCA
GGGATAACATCATTAAATTATAAAAGAAAAGATAAAAATAAAATTGATCATTCGAAAGAAATATTATTTCATAGGAAACCATTAAA
AGGTTTTTATGATGTTAAAGATGAACAAAATATTAATGATGATATATATGAAAATAATAAGACAAATCAGAAGAAAAGTATAAAAT
CAATGGATGTTGAAAATATTAATGATGCTATGGAATATAATAAAAATAAAGGTAAACGACAACATCAACATAATAATAATGAAGAA
GCAAATTTGTTATCTACCATAGAAAATTATGATAAACAATTTAACGAATTAAGTCATTTAAGAAAAAGGGTTCGATTGAATTTACC
AGAACCTATATTAAATGAAAATGAAATAGATGAAATAATACAAATAAATAAAGAAGCATCAGCATTTAACGATATTATAAAAGATC
AAAACGATAAATTACCAATAAATAATATTTTACCAAGTATTGAAAGCTCCTCATTTATATTAAACAATAAAGATAAATTTTCAAAC
TTGGAAACAGATTTTTATAATAATAATAATAATAAATCAATTGCTTTTTCTAGTAAACTAGATCTAAGTATACAACAAGCAGCAAA
AAATATCATTTCTCGAAAAATGAATATTCCATTTATAGGAATGAACAATGATTATAATGAAGAAGAATTCGAAAGAAAAAATAATA
TATTTCAAAAGAGTAATAAGAATGTTCCTGATGATTTAGAATATGATGACACGAACAATTATCATAATAATAATAATAATAATAAT
AATAATACTTCTTTTAATTCGATCAAAAATTCCACAACCCTTTATAATCATTTGGATGTAGAAAAAAATATAAAAGACGTACAAGA
AGAAATTGAAAAACAAAAGAAATTAAATGAAGAAGATCAACAAAAGAATCAAAAAGAAAAGTTAACTATTAAAAATAAAATTATTA
GTGATATTAAAAGTTTTAAAAAAAATATTAGTTTATATGCTCATTCTATTATTTCTTATAAAAATTTAAAAAATGATCAATCTATG
ATGGATAATCAAACTATACAAACAACTGAATATTATGATGATAATTATGAAGAGAAAATCGATCGAGCAAAATTACATATTAAAGC
ATCGTTAGCCAATTTACCCCAAGAAACGAATCTTATAGAACTTCAATTAAATGAAGAACATCCAGAATGTGATACGGACAATATAG
AAAAAGATGAAATAGAAAAAGATATACAAGATATTGAAAATGAAAAAAGAAAAAACGAAGAAAGAAAAGAAAAAGAAAAATTTAAT
AAGCAAAATAAAATTATTAGATGGAATTTACCTAGACCATATTTCTTAGATAAAATTAATCTCTTTAATAATTATATGCACAATGA
ATATGAAGATGTCCATAATTTAATACAAAGAGAGATGCTCCTCTTAATAAAAAATGATATGTTTAATTATCCCCTCAGAAATTCAA
CACCAGTACAAAATAAAGTTCATGTGGAAGATCTCGAAAACGTATACATGAATATGGCTATGAAGAGTATAAATGAGGAGTTCGAA
GATATGTATGGCGAAGCATCATTAAATAACAACACAAAGGATGATTCTAATATTGATGGGTGTGATGAAAAGAGTGATAATATTGA
TGGTTGTGATGAAAAAAGTGATACAACTAATAAAGGTGATGATACGTCCCAATGTAGTATCGAGCATAGTTCATATAATCATATCG
ATGTGTGGGAAGAAATTAACAAAAATATAATTTTTTGCCCATCAAAAAATGCATATCGCTTTATTGAAGATGTTAATGAAAACGAT
AAAAAAGAAAATTACAAATACAAATGTGAAAAATTAAAAAATTTAATTTTAAATGATATGGAACATTATAAAAAATTAGAAAATAA
ATATGATATTTATACAAAAGGATATCAACTAAAAATTAAAAGTTATAAAAAATCATATGATACTCTATTTAATTCATATATTAATT
GTATTAACGAAAAAGAAGCTTTAAATGTTCTACATGAAAATGAAAAAATATATGCATTAACAAGAATTAAAGAAGAAAAAAAGGAA
AATAAAAAAGAAATCGAATATCATAAATCATTACAAAAGTTTTATCAAGACCTTTTAGAAACAAATCATCAATTAAAAGAAACATG
TAAACAAACGTTAAAGGTGCCACTCGAGCACCACCATCACCATCACCATCACTAA 
 
 
A-7: PfMyb2-his fusion protein sequence  
Start codon encoded by the vector: M; Premature top codon: - 
Vector Sequence: Black 
Due to the BamHI site occurring out of frame a premature stop codon (TGA in A-6) is 
created and no PfMyb2 protein is produced.  
 
MAISRELVDP- 
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A-8: Sequence analysis of the PfMyb2 gene inserted into pGEX-4T-2 
  
Black sequence is from PlasmoDB while the coloured sequences represent the gene 
insert. 
The pGEX-4T-2 primer indicated as: 5’ 
The three designed, internal primers indicated as: INT1, INT2 and INT3  
The pGEX-4T-2 primers indicated as: 3’pGEX and 3’pGEX2  
 
Myb                1 ATGAGGATTCAAATAAAAGGAGGTATATGGAAAAATTGTGAGGATGAAGT     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5’                 1 ATGAGGATTCAAATAAAAGGAGGTATATGGAAAAATTGTGAGGATGAAGT     50 
                   
Myb               51 TCTTAAAGCAGCTGTTATGAAATATGGTTTAAATAATTGGTCAAGGGTCG    100 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||        
5'                51 TCTTAAAGCAGCTGTTATGAAATATGGTTTAAATAATTGGTCAAGGGTCG    100 
 
Myb              101 CATCTTTATTAGTTCGTAAATCAGCTAAACAGTGTAAGGCGAGGTGGTAT    150 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||        
5'               101 CATCTTTATTAGTTCGTAAATCAGCTAAACAGTGTAAGGCGAGGTGGTAT    150 
 
Myb              151 GAATGGCTTGATCCATCAGTTAGAAAAACCGAATGGAATAAAGAAGAAGA    200 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||        
5'               151 GAATGGCTTGATCCATCAGTTAGAAAAACCGAATGGAATAAAGAAGAAGA    200 
 
Myb              201 AGAAAAACTTTTACATCTAGCCAAATTGTTTCCAACACAATGGAGAACCA    250 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||        
5'               201 AGAAAAACTTTTACATCTAGCCAAATTGTTTCCAACACAATGGAGAACCA    250 
 
Myb              251 TAGCACCTATAGTAGGAAGAACAGCACAACAATGTTTAGAACATTATGAA    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               251 TAGCACCTATAGTAGGAAGAACAGCACAACAATGTTTAGAACATTATGAA    300 
 
Myb              301 TATCTACTTGATGAAGCGGAAGGAAAGGTTTATGATAAAAATAAGAACCC    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               301 TATCTACTTGATGAAGCGGAAGGAAAGGTTTATGATAAAAATAAGAACCC    350 
 
Myb              351 ACGACATCTAAGGCCAGGTGAAATAGACCCTGCTCCTGAATCCAAACCAG    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               351 ACGACATCTAAGGCCAGGTGAAATAGACCCTGCTCCTGAATCCAAACCAG    400 
 
Myb              401 CACGTGCAGATCCTGTAGATATGGATGAAGATGAAAAAGAAATGCTTGCA    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               401 CACGTGCAGATCCTGTAGATATGGATGAAGATGAAAAAGAAATGCTTGCA    450 
 
Myb              451 GAAGCTAAGGCAAGACTTGCAAATACGAAAGGTAAAAAAGCAAAAAGAAA    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               451 GAAGCTAAGGCAAGACTTGCAAATACGAAAGGTAAAAAAGCAAAAAGAAA    500 
 
Myb              501 AGCTAGAGAAAAACAACTGGAACAAGCTAGGAGATTAGCTTTATTACAAA    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
5'               501 AGCTAGAGAAAAACAACTGGAACAAGCTAGGAGATTAGCTTTATTACAAA    550 
 
Myb              551 AAAAGAGAGAATTAAAAGCAGCAGGGATAACATCATTAAATTATAAAAGA    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1               1 AAAAGAGAGAATTAAAAGCAGCAGGGATAACATCATTAAATTATAAAAGA     50 
 
Myb              601 AAAGATAAAAATAAAATTGATCATTCGAAAGAAATATTATTTCATAGGAA    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1              51 AAAGATAAAAATAAAATTGATCATTCGAAAGAAATATTATTTCATAGGAA    100 
 
Myb              651 ACCATTAAAAGGTTTTTATGATGTTAAAGATGAACAAAATATTAATGATG    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             101 ACCATTAAAAGGTTTTTATGATGTTAAAGATGAACAAAATATTAATGATG    150 
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Myb              701 ATATATATGAAAATAATAAGACAAATCAGAAGAAAAGTATAAAATCAATG    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             151 ATATATATGAAAATAATAAGACAAATCAGAAGAAAAGTATAAAATCAATG    200 
 
Myb              751 GATGTTGAAAATATTAATGATGCTATGGAATATAATAAAAATAAAGGTAA    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             201 GATGTTGAAAATATTAATGATGCTATGGAATATAATAAAAATAAAGGTAA    250 
 
Myb              801 ACGACAACATCAACATAATAATAATGAAGAAGCAAATTTGTTATCTACCA    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             251 ACGACAACATCAACATAATAATAATGAAGAAGCAAATTTGTTATCTACCA    300 
 
Myb              851 TAGAAAATTATGATAAACAATTTAACGAATTAAGTCATTTAAGAAAAAGG    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             301 TAGAAAATTATGATAAACAATTTAACGAATTAAGTCATTTAAGAAAAAGG    350 
 
Myb              901 GTTCGATTGAATTTACCAGAACCTATATTAAATGAAAATGAAATAGATGA    950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             351 GTTCGATTGAATTTACCAGAACCTATATTAAATGAAAATGAAATAGATGA    400 
 
Myb              951 AATAATACAAATAAATAAAGAAGCATCAGCATTTAACGATATTATAAAAG   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             401 AATAATACAAATAAATAAAGAAGCATCAGCATTTAACGATATTATAAAAG    450 
 
Myb             1001 ATCAAAACGATAAATTACCAATAAATAATATTTTACCAAGTATTGAAAGC   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             451 ATCAAAACGATAAATTACCAATAAATAATATTTTACCAAGTATTGAAAGC    500 
 
Myb             1051 TCCTCATTTATATTAAACAATAAAGATAAATTTTCAAACTTGGAAACAGA   1100 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||        
INT1             501 TCCTCATTTATATTAAACAATAAAGATAAATTTTCAAACTTGGAAACAGA    550 
 
Myb             1101 TTTTTATAATAATAATAATAATAAATCAATTGCTTTTTCTAGTAAACTAG   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             551 TTTTTATAATAATAATAATAATAAATCAATTGCTTTTTCTAGTAAACTAG    600 
 
Myb             1151 ATCTAAGTATACAACAAGCAGCAAAAAATATCATTTCTCGAAAAATGAAT   1200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT1             601 ATCTAAGTATACAACAAGCAGCAAAAAATATCATTTCTCGAAAAATGAAT    650 
 
Myb             1201 ATTCCATTTATAGGAATGAACAATGATTATAATGAAGAAGAATTCGAAAG   1250 
                     |||||||||||||||||||||||||||||||||||||||            
INT1             651 ATTCCATTTATAGGAATGAACAATGATTATAATGAAGAA               689 
                                           |||||||||||||||||||||||||||| 
INT2               1                       ATGATTATAATGAAGAAGAATTCGAAAG     28 
 
Myb             1251 AAAAAATAATATATTTCAAAAGAGTAATAAGAATGTTCCTGATGATTTAG   1300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2              29 AAAAAATAATATATTTCAAAAGAGTAATAAGAATGTTCCTGATGATTTAG     78 
 
Myb             1301 AATATGATGACACGAACAATTATCATAATAATAATAATAATAATAATAAT   1350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2              79 AATATGATGACACGAACAATTATCATAATAATAATAATAATAATAATAAT    128 
 
Myb             1351 AATACTTCTTTTAATTCGATCAAAAATTCCACAACCCTTTATAATCATTT   1400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             129 AATACTTCTTTTAATTCGATCAAAAATTCCACAACCCTTTATAATCATTT    178 
 
Myb             1401 GGATGTAGAAAAAAATATAAAAGACGTACAAGAAGAAATTGAAAAACAAA   1450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             179 GGATGTAGAAAAAAATATAAAAGACGTACAAGAAGAAATTGAAAAACAAA    228 
 
Myb             1451 AGAAATTAAATGAAGAAGATCAACAAAAGAATCAAAAAGAAAAGTTAACT   1500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             229 AGAAATTAAATGAAGAAGATCAACAAAAGAATCAAAAAGAAAAGTTAACT    278 
 
Myb             1501 ATTAAAAATAAAATTATTAGTGATATTAAAAGTTTTAAAAAAAATATTAG   1550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             279 ATTAAAAATAAAATTATTAGTGATATTAAAAGTTTTAAAAAAAATATTAG    328 
 
Myb             1551 TTTATATGCTCATTCTATTATTTCTTATAAAAATTTAAAAAATGATCAAT   1600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             329 TTTATATGCTCATTCTATTATTTCTTATAAAAATTTAAAAAATGATCAAT    378 
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Myb             1601 CTATGATGGATAATCAAACTATACAAACAACTGAATATTATGATGATAAT   1650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             379 CTATGATGGATAATCAAACTATACAAACAACTGAATATTATGATGATAAT    428 
 
Myb             1651 TATGAAGAGAAAATCGATCGAGCAAAATTACATATTAAAGCATCGTTAGC   1700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             429 TATGAAGAGAAAATCGATCGAGCAAAATTACATATTAAAGCATCGTTAGC    478 
 
Myb             1701 CAATTTACCCCAAGAAACGAATCTTATAGAACTTCAATTAAATGAAGAAC   1750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             479 CAATTTACCCCAAGAAACGAATCTTATAGAACTTCAATTAAATGAAGAAC    528 
 
Myb             1751 ATCCAGAATGTGATACGGACAATATAGAAAAAGATGAAATAGAAAAAGAT   1800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             529 ATCCAGAATGTGATACGGACAATATAGAAAAAGATGAAATAGAAAAAGAT    578 
 
Myb             1801 ATACAAGATATTGAAAATGAAAAAAGAAAAAACGAAGAAAGAAAAGAAAA   1850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT2             579 ATACAAGATATTGAAAATGAAAAAAGAAAAAACGAAGAAAGAAAAGAAAA    628 
                                            ||||||||||||||||||||||||||| 
INT3               1                        AAGAAAAAACGAAGAAAGAAAAGAAAA     27 
 
Myb             1851 AGAAAAATTTAATAAGCAAAATAAAATTATTAGATGGAATTTACCTAGAC   1900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3              28 AGAAAAATTTAATAAGCAAAATAAAATTATTAGATGGAATTTACCTAGAC     77 
 
Myb             1901 CATATTTCTTAGATAAAATTAATCTCTTTAATAATTATATGCACAATGAA   1950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3              78 CATATTTCTTAGATAAAATTAATCTCTTTAATAATTATATGCACAATGAA    127 
 
Myb             1951 TATGAAGATGTCCATAATTTAATACAAAGAGAGATGCTCCTCTTAATAAA   2000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             128 TATGAAGATGTCCATAATTTAATACAAAGAGAGATGCTCCTCTTAATAAA    177 
 
Myb             2001 AAATGATATGTTTAATTATCCCCTCAGAAATTCAACACCAGTACAAAATA   2050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             178 AAATGATATGTTTAATTATCCCCTCAGAAATTCAACACCAGTACAAAATA    227 
 
Myb             2051 AAGTTCATGTGGAAGATCTCGAAAACGTATACATGAATATGGCTATGAAG   2100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Int3             228 AAGTTCATGTGGAAGATCTCGAAAACGTATACATGAATATGGCTATGAAG    277 
 
Myb             2101 AGTATAAATGAGGAGTTCGAAGATATGTATGGCGAAGCATCATTAAATAA   2150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             278 AGTATAAATGAGGAGTTCGAAGATATGTATGGCGAAGCATCATTAAATAA    327 
 
Myb             2151 CAACACAAAGGATGATTCTAATATTGATGGGTGTGATGAAAAGAGTGATA   2200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             328 CAACACAAAGGATGATTCTAATATTGATGGGTGTGATGAAAAGAGTGATA    377 
 
Myb             2201 ATATTGATGGTTGTGATGAAAAAAGTGATACAACTAATAAAGGTGATGAT   2250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Int3             378 ATATTGATGGTTGTGATGAAAAAAGTGATACAACTAATAAAGGTGATGAT    427 
 
Myb             2251 ACGTCCCAATGTAGTATCGAGCATAGTTCATATAATCATATCGATGTGTG   2300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             428 ACGTCCCAATGTAGTATCGAGCATAGTTCATATAATCATATCGATGTGTG    477 
 
Myb             2301 GGAAGAAATTAACAAAAATATAATTTTTTGCCCATCAAAAAATGCATATC   2350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             478 GGAAGAAATTAACAAAAATATAATTTTTTGCCCATCAAAAAATGCATATC    527 
 
Myb             2351 GCTTTATTGAAGATGTTAATGAAAACGATAAAAAAGAAAATTACAAATAC   2400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             528 GCTTTATTGAAGATGTTAATGAAAACGATAAAAAAGAAAATTACAAATAC    577 
 
Myb             2401 AAATGTGAAAAATTAAAAAATTTAATTTTAAATGATATGGAACATTATAA   2450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             578 AAATGTGAAAAATTAAAAAATTTAATTTTAAATGATATGGAACATTATAA    627 
 
Myb             2451 AAAATTAGAAAATAAATATGATATTTATACAAAAGGATATCAACTAAAAA   2500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             628 AAAATTAGAAAATAAATATGATATTTATACAAAAGGATATCAACTAAAAA    677 
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Myb             2501 TTAAAAGTTATAAAAAATCATATGATACTCTATTTAATTCATATATTAAT   2550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
INT3             678 TTAAAAGTTATAAAAAATCATATGATACTCTATTTAATTCATATATTAAT    727 
                                                    ||||||||||||||||||| 
3'Pgex             1                                ATTTAATTCATATATTAAT     19 
 
Myb             2551 TGTATTAACGAAAAAGAAGCTTTAAATGTTCTACATGAAAATGAAAAAAT   2600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
3'Pgex            20 TGTATTAACGAAAAAGAAGCTTTAAATGTTCTACATGAAAATGAAAAAAT     69 
 
 
Myb             2601 ATATGCATTAACAAGAATTAAAGAAGAAAAAAAGGAAAATA--AAAAAGA   2648 
                     ||||||||| |||||||||||||||||||||||||||||||  ||||||| 
3'Pgex            70 ATATGCATT-ACAAGAATTAAAGAAGAAAAAAAGGAAAATA--AAAAAGA    116 
                     ||||.||||||||||||||||||||||||||||||||||||  |||.||| 
3'Pgex2            1 ATATaCATTAACAAGAATTAAAGAAGAAAAAAAGGAAAATAAGAAAGAGA     50 
 
 
Myb             2649 AATCGAATATCATAAATCATTACAAAAGTTTTATCAAGACCTTTTAGAAA   2698 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
3'Pgex2           51 AATCGAATATCATAAATCATTACAAAAGTTTTATCAAGACCTTTTAGAaA    100 
  
Myb             2699 CAAATCATCAATTAAAAGAAACATGTAAACAAACGTTAAAGGTGCCATAA   2748 
                     |||||||||||||||||||||||||||||||||||||||||||||||... 
3'Pgex2          101 CAAATCATCAATTAAAAGAAACATGTAAACAAACGTTAAAGGTGCCACTC    150 
 
 
Two sequencing reactions were carried out with the 3’ pGEX-4T-2 primer as there 
appeared to be a base change and insertion at positions 74 and 79 of the pGEX 
sequence respectively (in black box). When compared to the other sequencing 
reaction (pGEX2) using the same primer this substitution was not noted but there 
were other base insertions and changes downstream of this second sequence (in red 
box). In the figure below, the ticks and crosses represent what is correct and incorrect 
respectively. If one of either of the sequencing reactions had the correct base the 
sequence was considered correct.  
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